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During my PhD training I have extensively investigated the suitability of a perfusion-based 
bioreactor culture system to maintain primary colorectal cancer tissues. 
This thesis consists of a first chapter that includes a general Introduction covering 
important aspects related to the development, staging, prognosis and therapies in colorectal 
cancer and function of the principal components of the tumor microenvironment. Finally, I 
extensively discuss novel bidimensional and tridimensional in vitro models to predict drug 
responsiveness in colorectal cancer.  
The following three chapters include a comprehensive description of the Methods used and 
the Results obtained. Major findings are then commented in the Discussion.  This part 
represent a manuscript, which is currently under revision.  
Finally, in the Perspectives, I discuss future possible application of the perfused-based 
bioreactor system. In particular, I report preliminary results obtained with glycogen and 
human serum albumin nanoparticles, developed using an innovative ultrasonic technique 
during my visit at the Nanostructured Interfaces and Materials Science Group lead by 
Professor Frank Caruso at the University of Melbourne, Australia.  
During my PhD studies, I also contributed to writing a review focusing on In Vitro Modeling 
of Tumor–Immune System Interaction that is included as appendix.  
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Introduction 
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, often 
diagnosed in advanced stage. Chemotherapeutic regimens currently in use for human CRC 
show limited success rates, underlying the need of novel and personalized therapeutic 
schemes.  
 A pre-requisite for the development of tailored treatments is the possibility to predict patient 
responsiveness. However, a major challenge is represented by the lack of adequate in vitro 
models. 
The heterogeneous tissue composition of CRC patients has been recognized to play a key role 
in response to treatment due to the interaction between cancerous and non-transformed cells 
within the tumor microenvironment. However, all novel experimental approaches proposed 
for the evaluation of tumor drug responses, including primary cell cultures or 
xenotransplantation of cancer specimens in immunodeficient animals, result in loss or 
dramatic modifications of the tumor microenvironment. Thus, the development of adequate in 
vitro models allowing maintenance of whole CRC microenvironment is urgently needed. 
Aim 
During my PhD training, I have investigated the suitability of a perfusion- based bioreactor- 
culture system to maintain primary CRC tissues.  
In particular, I addressed: 
1. The maintenance of the heterogeneity of CRC microenvironment as compared to static 
cultures. 
2. The assessment of drug responsiveness of primary CRC tissues. 
Method 
Freshly excised CRC specimens were cut into fragments, inserted between two collagen type 
I sponges in a “sandwich-like” format and cultured for three days in a perfused-based 
bioreactor system or under static conditions.  
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Fresh tissues, tissues cultured under perfusion and static conditions were weighted and 
subjected to histomorphological evaluation. Percentage of epithelial cells was evaluated upon 
hematoxylin and eosin staining. Number of stromal, hematopoietic cells and total cell nuclei 
were counted using CellProfiler image analysis software following staining for vimentin, 
CD45, and DAPI, respectively. Viability of tumor cells was assessed upon Ki67 and cleaved 
caspase 3 staining. The preservation of functionality of tumor-associated stromal cells in 
perfused cultures was evaluated by assessing release of IL-6 upon stimulation with IL-17. For 
assessment of immune cells, IL-2 and IFN- release upon activation with  
Phytohaemagglutinin was measured. Finally, drug responsiveness of CRC tissue in perfused 
cultures, was evaluated by assessing proliferation and apoptosis of tumor cells to the 
conventional chemotherapeutic 5-Fluorouracil, upon Ki67 and cleaved caspase 3 staining, 
respectively.  
Results 
Our results showed that CRC tissues cultured under perfusion preserve the tissue mass at 
higher extent as compared to static cultures. Moreover, perfused tissues maintained higher 
tissue cellularity in comparison to static cultures.  
Tumor cells cultured under perfusion displayed an almost intact structure, as compared to the 
original tumors, and were viable and proliferating. In addition, stromal cells were maintained 
in proportions similar to those of original tumors and fully viable, as indicated by 
responsiveness to micro-environmental stimuli, such as IL-17. Furthermore, immune cells 
were also partially preserved, and were capable of releasing effector cytokines, such as IL-2 
and IFN-, upon activation by mitogenic stimulation. 
In contrast, in cultures performed under static conditions, fewer viable tumor and stromal 
cells were preserved, whereas immune cells were completely lost. In fact, in static cultures, 
percentages of proliferating cells were significantly reduced, whereas those of apoptotic cells 
were significantly increased. 
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Importantly, perfusion-based cultures proved suitable for testing the sensitivity of primary 
tumor cells to chemotherapies of current use in CRC. Indeed, following three days of 
treatment with 5-fluouracil (5-FU), an overall significant reduction in percentages of 
epithelial proliferating cells, and a significant increase in the fraction of apoptotic cells could 
be observed. Notably, analysis of individual samples revealed heterogeneous responses across 
different tumors.  
Conclusions 
Our results cumulatively suggest that primary CRC culture under perfusion preserve the 
microenvironment with its native tissue architecture and composition. Importantly, our culture 
system also preserves viability and functionality of non-transformed cells, including 
mesenchymal stromal cells and tumor infiltrating lymphocytes. 
Moreover, bioreactor-based cultures are amenable for testing sensitivity of primary CRC 
tissues to currently used chemotherapies and reveal heterogeneous responsiveness across 
different samples. 
Thanks to its capacity to maintain TME heterogeneity, our system may allow personalized 
drug testing within a more physiological context. Our culture system may also prove suitable 
for testing therapies whose efficacy is influenced by whole TME, such as drug-loaded 
nanoparticles and emerging stroma-targeted therapies currently under clinical investigation 
for CRC. Furthermore, we envisage validating its ability to predict patient-specific clinical 
responses in the context of follow-up studies.  
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1. Human colorectal cancer 
1.1 Epidemiology 
Colorectal Cancer (CRC) is the fourth most common cause of cancer-related death and the 
third major cause of morbidity and mortality worldwide 1. 
From 1998 to 2005 CRC incidence rates have declined which might be attributed to improved 
screening programs for the detection of precancerous polyps. However, CRC incidence and 
mortality remains still very high. It is, in fact, estimated that every year over 394,000 deaths 
from CRC still occur worldwide 1.  
Over 14.1 million cases recorded in 2002 all over the world 2. However, CRC is not 
uniformly distributed throughout the world. In particular, CRC mainly occurs in developed 
countries. Indeed, countries with the highest incidence rates include Australia, New Zealand, 
Canada, the United States and Europe. Modifiable risk factors associated with CRC incidence 
include physical inactivity, over-weight, cigarette-smoking, alcohol intake and diets reach in 
fats and poor in calcium, fibers, fruits and vegetables typical of the Western diet. Non-
modifiable risk factors include age1, genetic factors3, gender and race/ethnicity 4. In particular, 
most of CRC are diagnosed after the age of 40 and in particular occurs in people aged 50 or 
older 1,5,6. 
It affects more women than men  with CRC incidence and mortality has been reported to be 
slightly higher in women (10.1%)  than in men (9.4%)1,7. Moreover, women have a higher 
risk of developing right-sided (proximal) colon cancer than men, which is associated with 
more aggressive form of neoplasia compared to left-sided (distal) colon cancer 8. 
Race/ethnic disparities among the colorectal cancer population is well documented with non-
Hispanic Black males and females having the highest incidence and mortality, and 
Hispanics/Latino females and American Indian/Alaskan Native males having the lowest 
rates9. 
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In addition, a history of previous colon polyps, inflammatory bowel disease 10 , such as 
ulcerative colitis or Crohn's disease, or hereditary factors are associated with the increase in 
the incidence of CRC 5.  
1.2 Pathogenesis 
CRC arises as the result of an ordered series of events beginning with the transformation of 
normal epithelium into an invasive adenocarcinoma. 
Most cases (88% - 94%) of CRC are sporadic 11 and develop through different pathways of 
molecular events characterized by inactivation of tumor suppressor genes and oncogenes 
according to the adenoma-carcinoma sequence model, proposed by Fearon and Vogelstein in 
1990 (Figure I.1).  
 
Figure I.1 - Adenoma to carcinoma sequences 12 
Mutations of APC occur in a high proportion of sporadic colorectal carcinomas (up to 80%) 
13. Inactivation of both copies (alleles) of the APC gene located on chromosome 5 constitutes 
an early event in colorectal tumorigenesis14. The canonical tumor suppressor function of APC 
is to form a “destruction complex” with Axin/Axin2 and GSK-3β that promotes the 
ubiquitination and subsequent degradation of the oncogene β-catenin in the absence of Wnt 
signaling. Loss of APC function results in an accumulation of β-catenin, which translocates to 
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the nucleus and lead to stimulation of cellular growth and proliferation and to the disruption 
of differentiation programs 15. 
5–10% of CRC are hereditary 11, such as the familial adenomatous polyposis (FAP) and 
hereditary nonpolyposis colorectal cancer (HPNCC). 
The HPNCC, also known as Lynch Syndrome, is the most common form of hereditary 
cancers and is characterized by the alteration in at least six of the responsible mismatch repair 
(MMR) genes including MSH2, MSH3, MSH6, MLH1, PMS1, and PMS2 16. The mutation of 
the MMR genes leads to an accumulation of DNA replication errors. This phenomenon is 
known as microsatellite instability (MSI) and can be identified in more than 90% of CRC 
affect by the Lynch syndrome. According to their MS status, CRC MSI can be further 
classified into MSI-high (MSI-H), MSI-low (MSI-L), or microsatellite-stable.  
Epigenetic mechanisms are also involved in the colorectal carcinogenesis and might impact 
on MS status. For instance, the so called “CpG island methylator phenotype “(CIMP) refers to 
a subset of tumors which present a methylation of CpG islands resulting in inactivation of one 
of several tumor suppressor genes or other tumor-related genes. Notably, most CIMP CRCs 
are characterized by promoter CpG island methylation of the mismatch repair gene, MLH1, 
resulting in its transcriptional inactivation 17. These CRCs, although sporadic, are also 
characterized by MSI-H status 18. 
1.3 Staging and prognosis 
CRC cancer staging, proposed by the American Joint Committee on Cancer (AJCC) and the 
International Union for Cancer Control (UICC), is based on histopathologic evaluation and 
operative findings of excised tissues, i.e., the local invasion depth (T stage), lymph node 
involvement (N stage), and presence of distant metastases (M stage). TNM classification is 
used to predict prognosis and provides the basis for therapeutic decisions. CRC survival 
ranges from 90% for stage I CRC to 10% in patients with stage IV disease 1. However, 
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patients with early stage may have approximately 20-30% risk of recurrence indicating that 
the currently used TNM staging system may not reflect the individual cancer aggressiveness 
19.   
Several efforts have been made regarding the identification of tumor related features that 
might represent further important prognostic factors such as lymphocytic infiltration, venous 
invasion, circumferential margin status, and tumor budding (i.e., presence of single cells or 
small clusters at the invasive margin) 20. In addition, MSI analysis can also provide important 
information about prognosis and therapy response. Patients with MSI-H show a better 
prognosis as compared to patients with MSS tumors21. Moreover, MSI-H CRCs do not benefit 
from adjuvant therapy (see below) with 5-fluorouracil (5-FU) whereas show an improved 
response to irinotecan-based chemotherapy 22.  
1.4 Standard therapies 
For patients with early stage CRCs (stage I – II), surgery is the only treatment option. 
Neoadjuvant radiotherapy is reserved for patients with rectal cancer whereas postoperative 
chemotherapy is usually a postoperative treatment option for patients with positive lymph 
nodes (stage III or high-risk stage II CRC) and the front-line treatment for stage IV patients.  
The most of in use standard therapies target tumor cells o tumor cell-derived factors. In 
particular, the common standard therapy is represented by a combination of chemotherapy 
agents, mainly  including 5-FU, a fluorinated pyrimidine that inhibit the action of the 
thymidylate synthase, an enzyme involved in pyrimidine nucleotide synthesis, thus stopping 
DNA replication.  
5-FU is usually combined with leucovorin, a reduced folate, which enhance the inhibition of 
DNA synthesis by stabilizes the binding of 5-FU to thymidylate synthase, and with 
oxaliplatin, a platinum derivative that forms inter- and intra- strand cross links in DNA, which 
prevent DNA replication and transcription, thus inducing cellular apoptosis. The combination 
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of 5-FU, leucovorin and oxaliplatin is known as FOLFOX.  Irinotecan is also used in CRC 
treatment and its mechanism of action is based on the inhibition of the topoisomerase I, an 
enzyme involved in the uncoiling of DNA during replication and transcription. Irinotecan is 
used in CRC treatment either alone or in combination with leucovorin and 5-FU. This 
regimen is known as FOLFIRI. 
While 5-FU used as single agent in patients with metastatic colorectal cancer has an objective 
response rate around 20%, the administration of FOLFOX or FOLFIRI 23 results in 
significantly increased response rates up to 40% of treated patients 24,25. However, the side 
effects of systemic therapy such as myelotoxicity, neurotoxicity or gastrointestinal toxicity 
may lead to complications which may affect impact on the quality of life of the patients 23. 
Besides these cytotoxic chemotherapies newly targeted strategies have been recently 
introduced, aiming at interrupting cellular pathways essential for tumor growth and survival. 
An example is represented by antibodies blocking the epidermal growth factor receptor 
(EGFR), such as Cetuximab and panitumab  26, which have been approved for treatment of 
metastatic colorectal cancer as single agents or in combination with other chemotherapies.  
Currently, two epidermal growth factor receptor antagonists: Cetuximab and panitumab  26 
have been approved for treatment of metastatic colorectal cancer as single agents or in 
combination with other chemotherapies. According to the results of the international 
ASPECCT trial, the first randomized phase III study evaluating the two EGFR-targeted 
monoclonal antibodies in patients with chemorefractory KRAS wild-type metastatic 
colorectal cancer (mCRC) metastatic CRC, Panitumumab (Vectibix) proved non-inferior to 
cetuximab (Erbitux) in extending overall survival (OS) 27. The response rate when 
panitumumab is associated with irinotecan is 34% while it is 20% when cetuximab is 
administrated in combination with irinotecan 28.  
However, anti-EGFR antibodies are not effective in the presence of mutations of the rat 
sarcoma virus (RAS) family gene, including KRAS, NRAS and HRAS, which, under normal 
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conditions, regulate the extracellular signaling to deliver growth signals from the epithermal 
growth factor (EGFR) to the nucleus. In tumor, RAS mutations lead to the disruption of the 
normal signaling pathway and so to aberrant growth and metastasis. It has been estimated that 
RAS mutations occur in 30-40% of CRC 29.  
Another targeted treatment which has been used in combination with standard 
chemotherapeutic agents in several clinical trials in patients with advanced CRC is the 
angiogenesis inhibitor Bevacizumab 30, a humanized antibody directed against the vascular 
endothelial growth factor (VEGF). Results showed that Bevacizumab resulted in an improved 
tumor response as compared with fluorouracil and leucovorin alone 31. 
Targeting angiogenesis has also been achieved by using tyrosine kinase inhibitors (TKIs).  
However, the role of the TKIs is not yet fully clarified 32 and a better understanding of novel 
combinations with TKIs that could prove more efficacious are urgently needed 33. 
In conclusion, the introduction of more complex protocols in addition to 5-FU, as well as the 
development of targeted therapies has resulted in a significant improvement in the treatment 
options for CRC. However, to find a system which may reliably predict responsiveness of 
individual patients to different drugs remains a critical need.  
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2. CRC microenvironment 
2.1 Determinants of CRCmicroenvironment 
The tumor microenvironment (TME) comprises tumor cells and non-transformed cells, 
including immune cells, endothelial cells, and stromal fibroblasts, and the extracellular matrix 
(ECM). These cells communicate through a complex network of interactions such as through 
a direct cell-cell contact or through soluble and insoluble factors and signaling molecules.   
 
Figure I.2 - Cellular constituents of the tumor microenvironment. The tumor 
microenvironment consists of complex cellular and molecular and constituents. The cellular 
constituents consist of immune cells of hematopoietic origin and stromal cells of non-
hematopoietic origin. The immune cell compartment comprises tumor-infiltrating 
lymphocytes and tumor-associated myeloid populations. The stromal compartment consists of 
cancer-associated fibroblasts and endothelial cells of the lymphatic and blood vasculature 34 
It is now well recognized that non-malignant cells of the TME have a heavily impact on 
tumor development and progression in all the stages of CRC carcinogenesis 35. Therefore, to 
develop novel effective therapies, it is necessary to have a clear understanding of the TME 
key players in tumor progression. 
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2.1.1 The extracellular matrix  
The extracellular matrix (ECM) is an organized three–dimensional structure that provides a 
structural scaffold for cells, regulates cell migration, differentiation and proliferation. The 
ECM is composed by five macromolecules: the most abundant component is collagen 
followed by laminins, fibronectin proteoglycans, glycosaminoglycans and hyaluronans. 
Changes in ECM composition lead to changes in physical cues such as rigidity and cells 
respond to these forces through changes in cell division, migration, gene expression. Tumors 
are usually stiffer than the surround healthy tissue. 
In fact, a recent study demonstrates that the accumulation of P-selectin-mediated platelet up-
regulates the ECM modifying enzyme lysyl oxidase (LOX) which mediates the cross-linking 
of collagen and elastin thus increasing the ECM stiffness. Therefore, a stiffer matrix drives 
CRC development and progression and might be associated with poor prognosis 36. 
2.1.2 Cancer-associated fibroblasts 
Fibroblasts are responsible for the ECM secretion and they are the main component of the 
reactive stroma in primary and metastatic CRC where they are known as cancer-associated 
fibroblasts (CAFs). 
CAFs are a heterogeneous population of cells with various origins, the majority of which are 
derived from resident fibroblasts37. CAFs may also be derived from other cells, including 
mesenchymal stem cells (MSCs), pericytes, adipocytes and endothelial cells, or epithelial 
cells via epithelial–mesenchymal transition (EMT) 38 . CAFs in the tumor stroma can be 
differentiated according to their morphology and specific identifiable markers. CAFs are 
generally presented as large spindle-shaped cells similar to smooth muscle cells 
(myofilaments and electron dense patches). Commonly used markers to identify CAFs are α-
SMA, fibroblast activation protein-α (FAP-α), fibroblast-specific protein-1 (FSP-1/S100A4), 
or platelet-derived growth factor receptor-β (PDGFR-β) 39. Numerous previous studies have 
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highlighted a pro-tumorigenic role for CAFs that can stimulate tumor cell proliferation, 
survival, migration, and invasion via secretion of various growth factors, cytokines, such as 
hepatocyte growth factor HGF, TGF-β, interleukin-6 (IL-6), stromal cell-derived factor-1α, 
IL-1β and TNFα 40, and chemokines such as CXCL12, CXCL14 and CCL5. 
In particular, levels of IL-6 in serum has been associated with poor patient prognosis, possibly 
due to its ability to promote tumor cell survival and support the production of vascular 
endothelial growth factor (VEGF). 
TGF-β has been recognized to have an oncogenic activity by inducing epithelial-to-
mesenchymal transition (EMT), which is characterized by a change in cell shape from a 
polarized epithelial cell to a flattened fibroblast-like cell, a decrease in cell–cell contacts and 
increased cell motility, which in turn enhances tumor cell migration. In addition, TGF-β can 
also indirectly influence tumor growth by inducing fibroblast differentiation, thus leading to 
tumor tissue remodeling and supporting tumor cell growth. Moreover, TGF-β induce the 
expression of VEGF and connective tissue growth factor (CTGF), thus enhancing the 
recruitment of endothelial cells to the tumor, leading to the formation of new vessels and 
allowing tumor growth 41. 
In addition, CAFs secrete ECM and proteases, such as matrix metalloproteases, cathepsins, 
and plasminogen activators, and thereby induce EMT and promote invasive growth of colon 
cancer cells 38. In particular, by expressing elevated amounts of matrix metalloproteinases, 
CAFs play a critical role in the degradation of the basal membrane (BM). The loss in integrity 
of the BM allows for invasion by cancer cells which migrate freely through the gaps formed 
in BM, thus promoting cancer metastasis 42. 
Herrera et al. demonstrated that patients with high “CAF signature” had a remarkably poor 
prognosis 43. Moreover, expression of FAP has been shown to be associated with an 
aggressive disease and to be an independent negative prognostic factor in CRC patients 44,45. 
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Calon et al. found that active TGF-β signaling in CAFs increases the frequency of tumor-
initiating cells, whereas, in patient-derived tumor organoids and xenografts, inhibitors of 
TGF-β signaling block the cross-talk between cancer cells and fibroblasts and prevent 
metastatic spread 46. 
Isella et al. confirmed that the CAF signature was associated with poor prognosis in untreated 
colon cancer patients and also predicted resistance to radiotherapy in rectal cancer 47. 
Taken together these studies confirmed that CAFs significantly contributes to clinical features 
of CRC and shapes the therapeutic response. 
2.1.3 Tumor infiltrating immune cells 
The immune cell types that may be observed within the TME include macrophages, dendritic 
cells, mast cells, natural killer (NK) cells, naïve and memory lymphocytes, B cells and T cells 
(e.g. T helper 1 (TH1), TH2, TH17 cells, regulatory T (Treg) cells, T follicular helper (TFH) and 
cytotoxic T cells). The number of infiltrating immune cells is extremely variable within the 
same tumor type, from different tumor locations and from patient to patient.  
T lymphocytes and macrophages are present at the core and invasive tumor margins. Whereas 
NK cells, myeloid-derived suppressor cells (MDSCs), mast cells and neutrophils are mostly 
located in the invasive margins. Finally, B lymphocytes and mature dendritic cells 
preferentially populate tertiary lymphoid islets (TLS) 48.  
The nature, location, functional orientation and density of the different tumor infiltrating 
immune cell populations is defined as “immune contexture”. A fairly new and promising 
concept is that the immune contexture can yield information that is relevant to prognosis and 
prediction of a treatment response.   
Tumor infiltration by adaptive immune cells, in particular effector T lymphocytes, has been 
reported to be associated with clinical outcome.  
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Figure I.3 - The immune contexture The immune cell compartment comprises tumor-
infiltrating lymphocytes of T, B, and natural killer cells and tumor-associated myeloid 
populations of dendritic cells, macrophages, and myeloid-derived suppressor cells 49. 
Ropponen et al. showed an inverse correlation between the presence of tumor-infiltrating 
lymphocytes (TILs) and tumor stage, i.e. TILs are more present in early stages (stage I and II) 
and decrease in advanced stages (stage III and IV) 50. 
More recently, it has been demonstrated that a high infiltration by CD3+, CD8+ and 
CD45RO+ cells at the core and invasive margin, clearly correlates with favorable prognosis 
51,52.   
These studies have led to the development of the “Immunoscore”, a mean of measuring T cell 
infiltrate into CRCs. The “Immunoscore” has shown to predict outcome more accurately than 
staging systems currently in use53.  
Innate immune responses, particularly those involving tumor associated macrophages 
(TAMs), have been studied and data show that the frequency of these cells infiltrating the 
tumor can be associated with poor patient outcome, although this is controversial 53. In 
contrast, decreased number of preoperative NK cells in patients with CRC was associated 
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with an increased frequency of postoperative tumor recurrence 54. Moreover, recent studies 
from our group showed that infiltration by neutrophils of the TME enhances the prognostic 
significance of colorectal cancer infiltration by CD8+ T cells, thus suggesting that they might 
effectively promote antitumor immunity 55. In addition, CRC infiltration by myeloperoxidase-
expressing neutrophil granulocytes is associated with favorable prognosis 56. 
2.1.4 Tumor-associated endothelial cells 
Additional cellular components of the TME include the endothelial cells, which are 
responsible for the formation of vascular structures which provide nutrients and oxygen. The 
induction of angiogenesis is an important early event in CRC development thus the 
microvascular density represents an important prognostic factor and might guide the 
therapeutic decision. Tumors are characterized by an overexpression of pro-angiogenic factors 
which lead to a structurally and functionally abnormal vasculature with leaky and tortuous 
blood vessels. This disorganized vasculature lead to an abnormal TME characterized by large 
hypoxic zones known to be much more resistant to several cytotoxic drugs than normoxic 
regions 57. Also leaking vessels generate elevate interstitial hypertension as well as an 
impaired blood flow which interfere with the delivery of therapeutics and lead to a 
heterogeneous microenvironment. In addition, solid tumors present a very poor lymphatic 
network than normal tissues, which contributes to the increased interstitial fluid pressure 
(Figure I.4). 
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Figure I.4 - Diagrammatic representation of the vascular system. A ) Normal tissue. B ) 
Solid tumor. Red represents well-oxygenated arterial blood, blue represents poorly 
oxygenated venous blood, and green represents lymphatic vessels 58. 
2.2 Therapies targeting CRC microenvironment 
Based on the evidence that also non-neoplastic cells heavily influences cancer progression, 
therapies targeting the host compartment of tumors have started to be exploited and applied in 
the clinic. 
In particular, great efforts have been made to develop novel therapies targeting CAFs. For 
example, as mentioned above, CAFs express a membrane-bound serine protease called 
fibroblast activation protein α (FAP) that is not detected in normal fibroblasts, and whose 
expression has been associated with an overall poorer prognosis in CRC. FAP is mainly 
localized in the stroma adjacent to tumor cells but not in the stroma of normal tissue, making 
it a very attractive candidate for tumor-targeted therapies. However, several studies targeting 
FAP with a humanized monoclonal antibody (sibrotuzumab) failed to produce clinical 
benefits in CRC 59. 
Advances in understanding the role of transforming growth factor (TGF)-β in tumorigenesis 
have led to the development of TGF-β inhibitors for cancer treatment. Three platforms of 
TGF- inhibitors have evolved: antisense oligonucleotides, monoclonal antibodies and small 
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molecules 60. In particular, for CRC treatment a TGF-β1-specific phosphorothioate antisense 
(AP-11014) and TGF-β2 inhibitors (Trabedersen, AP-12009) have been proposed 61. 
Several studies have shown the potential of targeting TGF-β signaling and, despite earlier 
predictions of severe toxicity, neutralizing antibodies to TGF-β have been well tolerated and 
have potent antimetastatic activity 62. 
Recently bispecific antibodies (bsAbs) have been introduced to stimulate effector cells to 
direct their cytotoxic effects against tumor cells. For example, bsAbs comprising a first 
antigen binding site specific for Death Receptor 5 (DR5) and a second antigen binding site 
specific for FAP have been introduced for CRC treatment have shown the capacity to strongly 
induce apoptosis in tumor cells in patient-derived xenograft models 63. 
Immunotherapy has offered promising results in CRC focusing on inducing efficient and 
specific cytotoxic responses mediated by CD8 T cells avoiding the side effects of 
chemotherapeutic drugs. In particular recently several approaches have been explored 
including checkpoint inhibitors64.  
T cells mediated immunity is strongly controlled by a balance system regulated by many 
stimulatory and inhibitory proteins. In particular, negative regulators of the immune system 
called immune checkpoints play a key role in inhibiting the immune response. These 
molecules are expressed on activated T cells, and upon binding their corresponding ligands, 
expressed on antigen presenting cells or tumor cells they suppress T cell activation. Thus, 
recent studies focused on the use of checkpoints-inhibiting agents (mainly PD-1/PD-L1 and 
CTLA4) for CRC therapies to interrupt the inhibition of the immune signal against tumors 
and restore the efficient immune response 65,66. In particular recent effort has been made to 
test an-anti-CTLA4 antibody (Ipilimumab) for CRC treatment 66. Ipilimumab have been 
already approved for metastatic melanoma treatment however it fails to demonstrate a similar 
success in CRC. Anti PD-1-mAb (nivolumab and pembrolizuman) have been approved for 
several type of cancers such as renal carcinoma, non-small cell lung carcinoma (NSCLC), 
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head and neck squamous cell carcinoma (HNSCC) and uretherial cancers however it resulted 
in a low response rate in CRC 65. Importantly, checkpoints inhibitors resulted in improved 
antitumor response in MSI-H cancers. The MSI-H are characterized by and higher T cells 
density as compared to MSS. However, tumor cells are not eliminated by the immune system 
due to the upregulation of inhibitory checkpoints. These data indicate that MSI-H cancers 
might be good candidates for checkpoint immunotherapy 67.  
Finally, a novel CEA IgG-based T-cell bispecific (TCB) antibody is currently in phase I 
clinical trials for the treatment of CEA-expressing solid tumors. CEA-TCB antibody 
recognizes CEA and CD3e via inducing T cell-mediated killing of CEA over-expressing 
tumors while sparing primary cells with low CEA expression 68 
2.3 Personalized and precision medicine for CRC 
Recently, many efforts have been made to tailor anticancer treatment to the individual 
patient’s characteristics. 
In December 2015, the EU Health Ministers in their “Council conclusions on personalized 
medicine for patients, defined the personalized medicine as a “medical model using 
characterization of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical 
imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the 
right time, and/or to determine the predisposition to disease and/or to deliver timely and 
targeted prevention.”  
The terms precision and personalized medicine have often been used interchangeably. 
However, the personalized medicine term imply that unique treatments can be designed for 
each individual whereas precision medicine approaches may lead to non-personalized 
interventions that can be used population-wide.  
Precision medicine requires a deep understanding of the genetic mutations in addition to the 
development of new targeted therapies that matches those genetic changes. 
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CRC have particularly benefit from the recent advances in precision medicine that aims to 
predict patient’s response to anticancer treatments using novel molecular tools. 
Genetic tests, such as RAS and MSI tests, are now available to assess risk, enhance prognosis 
and predict treatment response. In addition to tumor tissue genotyping, analysis of tumor 
DNA from liquid biopsy has been shown to provide a rapid test able to reflect the mutation 
status of tumor tissue. Additional tests intent to predict the toxicity of a specific anticancer 
treatment. For example, Theraguide 5-FU (Myriad Laboratories) is able to predict the 5-FU 
toxicity based on detection of the mutations in two genes involved in fluoropyrimidine 
metabolism. These tests might be useful to adjust the dose or to choose alternative therapeutic 
approaches. Finally, the advent of precision medicine, despite quite new for CRC medicine, is 
gradually becoming an integral part of the process of care by providing important tools to 
predict treatment outcomes.  
However, a pre-requisite for the development of tailored treatments is the possibility to 
predict patient responsiveness. Systems able to predict the individual response to the several 
anticancer treatments now available are still missing. 
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3. CRC models to predict drug responsiveness 
3.1 Two-dimensional (2D) CRC models 
A huge effort has been recently made to develop adequate in vitro models which may reliably 
predict tumor responsiveness to therapeutic treatments. 
Cell lines culture in dimensional monolayer have played a key role in the development of new 
anticancer drugs. In particular, Since the late 1980s, The US National Cancer Institute (NCI) 
60 human tumor cell line anticancer drug screen (NCI60), a panel of cancer cell lines 
representing nine distinct tumor including colon cancer, has been used as in vitro drug-
discovery tool. The most widely used cellular model for CRC has been the Caco-2 cell line, 
obtained from a human colon adenocarcinoma, reaching over 13,590 references in the 
PubMed database in April 2016.   
Despite being a powerful tool, cell lines do not maintain functional features of primary cells. 
Indeed, they may show different phenotypes, native functions and responsiveness to stimuli as 
compared with primary cells. Moreover, serial passage of cell lines can further cause 
genotypic and phenotypic modification.   
Furthermore, since almost all cells in the in vivo environment are surrounded by other cells 
and ECM in a three-dimensional (3D) fashion, 2D cell culture does not adequately take into 
account the natural 3D environment of cells including the oxygen, nutrients and metabolites 
distribution, 3D cell-cell and cell-matrix contact, which is well recognized to influence cell 
structure, adhesion, mechanotransduction and cell functions.  
Currently, in drug discovery, the standard procedure of screening compounds starts with the 
2D cell culture-based tests, followed by animal model tests, to clinical trials.  
Many of the drugs fail during clinical trials, especially during phase III 69, which is the most 
expensive phase of clinical development, largely due to the lack of clinical efficacy and/or 
unacceptable toxicity. A portion of these failures is attributed to data collected from the 2D 
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monolayer culture and in vivo tests in which the cellular response to drug(s) is altered due to 
their unnatural microenvironment. Indeed, many experimental animals have compromised 
immune systems and do not offer the same stroma-tumor interaction as humans, which 
prevents the efficient translation of novel research to clinical settings 70. Obtaining 
concordance between animal models and clinical trials still remains challenging (only 8% of 
concordant results) 71.  
These limitations have encouraged the emergence of many 3D methods to bridge the gap 
between in vitro and in vivo. 3D models offer a system to better translate the complex 
pathophysiological features of the TME in vitro. The ideal 3D model would eliminate the 
differences related to species that are usually encountered, allowing drug testing directly on 
human models. 
3.2 Cell lines-based 3D models  
Extensive evidence demonstrates that cells cultured in 3D mimic in vivo tumor conditions 
more closely than standard 2D culture with respect to cell morphology and organization, cell 
heterogeneity, protein and gene expression patterns, cell-cell and cell-matrix contact 72. 
Therefore, to date numerous 3D models have been developed to recreate in culture the 
complex 3D architecture of the CRC 73,74. Multicellular tumor spheroids are very small 
tridimensional cellular structures 75 which are generated in suspensions on an acellular 3D 
scaffold or by dispersing cells in a liquid matrix followed by solidification or polymerization 
(Figure I.5). 
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Figure I.5 - Bidimensional (2D) and multicellular spheroids cultures. Schematic diagrams 
of the 2D monolayer cell culture (A), scaffold-free cell spheroids in suspension (B) and 3D 
cell culture systems: cell spheroids grown on matrix (C), cells embedded within matrix (D). 
Adapted from Edmondson R. et al, 2014 70 
Commonly used scaffold/matrix materials used for the generation of multicellular spheroids 
include biologically derived scaffold systems, such as Matrigel (BD Matrigel™, BD 
Sciences), basement membrane extract (Cultrex® BME; Trevigen) or hyaluronic acid-based 
scaffolds,  and synthetic-based materials such as Polyethylene glycol (PEG), polyvinyl 
alcohol (PVA), polylactide-co-glycolide (PLG), and polycaprolactone (PLA).  
Recently, Piccoli et al. generate an organotypic 3D-bioactive model of CRC by seeding HT29 
tumor cells on decellularized human biopsies. This model retained major proteins and soluble 
factors of the ECM and preserved their biological activity in terms of cell attraction and 
pathway activation 76.  
Multicellular spheroids including different cell types, in addition to tumor cells, have also 
been proposed. 
Nyga et al. developed a complex 3D CRC model based on the co-culture of HT29 epithelial 
cell line, fibroblasts and endothelial cells seeded in collagen type I gel whereas in 2016, 
Nietzer et al, developed a 3D in vitro model of CRC based on the coculture of tumor and 
stromal cells on a biological scaffold derived from decellularized porcine jejunum (small 
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intestine submucosa, SIS) obtained a 3D in vitro CRC able to reflect human tissue-related 
tumor characteristics 77. 
As compared with the corresponding monolayer cultures, multicellular spheroids preserve the 
tridimensional structure, and the cell-cell and cell-ECM contact.  
Furthermore, they preserve the heterogeneity of in vivo tumor tissues inasmuch as are 
comprised of cells in different stages, including proliferating, quiescent, apoptotic, hypoxic, 
and necrotic cells. Indeed, the cells of the external layer of the spheroid are exposed to the 
medium and therefore are mainly viable and proliferating, whereas, the cells of the core 
receive less oxygen, growth factors, and nutrients from the medium, and tend to be in a 
quiescent or hypoxic state (Figure I.6). 
 
Figure I.6 - Models of oxygenation, nutrition, CO2 removal in a multicellular spheroid. 
Cells of the external layer are exposed to higher oxygen concentration and lower waste 
products as compared with the central region or the core thus presenting higher proliferative 
state 78. 
 In addition, cells cultured in 3D have shown a different proliferation rate as compared to 2D. 
For example, it has been demonstrated that that a variety of CRC cell lines on Laminin-rich-
extracellular matrix (IrECM) showed a reduced proliferation rate in 3D as compared with 2D 
cultures 70.  
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Cellular response to anticancer treatments in 3D has been shown to better reflect the in vivo 
sensitivity as compared to 2D cultures. In particular, several studies demonstrated that 3D 
models are more chemoresistant than 2D cultures.  For example, Karlsson et al. 79 showed that 
CRC HCT116 cells cultured in 3D spheroids were more resistant to several anticancer 
treatments (melphalan, 5-FU, oxaliplatin, and irinotecan) than in 2D.  
The multicellular resistance can be explained by the poor proliferation rate in the center and 
core of the spheroid since quiescent cells are not sensitive to most anticancer drugs 80.  
In addition, the increased drug resistance in 3D might be due to limited ability of drugs to 
penetrate the spheroid and to reach all the tumor cells and to hypoxia, which has been shown 
to lead to the activation of genes involved in cell survival and drug sensitivity 58. 
3.3 3D models based on primary cells 
It has been widely demonstrated that cell lines, despite maintaining some properties of the 
original cells, they show clear differences in genetics, epigenetics, and gene expression 
profiles as compared with primary cells 72. Thus, recent attempts have been made to develop 
3D models from human primary CRC cells.  
However, maintenance of primary CRC cells has proved very difficult, possibly due to the 
insufficient maintenance of cancer stem cells (CSCs), a rare subpopulation of cells with high 
self-renewal, under serum-based culture conditions conventionally used for cell lines. 
Ricci-Vitiani demonstrated that CD133+ CSCs sorted from primary CRC can be maintained 
in vitro as spheroids structures when cultured with 5% serum. However, this occured  with 
very variable efficiency 81. Kondo et al. showed that CRC spheroids from dissociated cell 
clusters, called “cancer tissue-originated spheroids” (CTOSs), cultured into collagen type I 
extracellular matrix, could be maintained for long periods (up to 14days) and can be passage 
(up to 22 times). However, in both the previous cited studies the spheroids culture the 
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efficiency was low (<50%)82.  Organoids are 3D stem cell cultures that self-organize into ex 
vivo 'mini-organs'. 
In 2009, Sato et al. proposed a robust method which enabled the production of self-renewing 
dysplastic intestinal organoids containing intestinal stem cells (ISCs), responsible for CRC 
expansion in vivo, which could be expanded indefinitely 83. CRCs crypts were cultured in a 
solubilized basement membrane (Matrigel) rich in matrix proteins, including laminin and 
collagen, to mimic the microenvironment of the crypt base in vivo, and supplemented with 
niche factors (EGF, Noggin, ALK4/5/7 and P38 inhibitor) to support crypt growth 84. 
It has been shown that intestinal crypt organoids are able to accurately predict the apoptotic 
response to 5-FU in the mouse intestinal epithelium than either of the conventionally used 
CRC cell lines Caco-2 or MC38 85. 
Overall, spheroids and organoid cultures resemble the complex spatial morphology of the 
native tissue and allow cell-cell and cell matrix interactions.  
One limitation of organoids and multicellular spheroid models is the limited growth over a 
long culture time: without blood perfusion, the passive diffusion of nutrient and O2 into the 
spheroids becomes insufficient to maintain the functions of the cells in the centre of the 
spheroids, which then causes significant necrosis when the spheroid diameter is >600 µm 86- 
In addition, those models lack the tissue heterogeneity. In fact, organoid cultures preserve the 
epithelial component but it is not clear whether they can maintain stromal or immune cells.  
Finally, whether the drug responses in organoid in vitro can predict clinical response, in 
patients still remains to be addressed. 83.  
Short-term culture (up to three days) of CRC explants in tumor-grade matched matrix has 
been proposed by Madjumder et al. for the prediction of tumor response to chemotherapy. 
The system maintains the original tissue architecture and matrix proteins components and has 
been shown to accurately predict response to tumor cell-targeted therapies 87. However, 
 
 
 
35 
whether stromal cells and immune cells also survived under these conditions was not 
assessed.  
3.5 3D CRC perfused models 
Recent advances in microfabrication techniques have created a unique opportunity to develop 
3D microfluidic platform that more accurately reflect in vivo human biology when compared 
with two-dimensional flat systems or animal models. 
Recent attempts have been made to recapitulate the leaky and tortuous microcirculation of 
solid tumors. Recently in vitro vascularized microtumors (VMTs) that incorporate human 
tumor and stromal cell line have been developed. The VMT platform provides a unique model 
for studying vascularized solid tumors in vitro 88. 
In 2013, Moya et al developed a microphysiological system of CRC organoids obtained from 
CRC cell line (SW620 and HCT116) and perfused by human microvessels using a pluripotent 
stem cell (iPSC) technology able to recapitulate the microcirculation of the tumor 89.  
More recently, 3D perfused tumor spheroids for anticancer drug testing have been developed 
starting from CRC DLD-1 cell line.  Spheroids in perfusion showed an improved cell viability 
and increased growth potential compared with spheroids cultured in static condition after over 
17 days of culture. Moreover, perfusion provided a more accurate prediction of drug toxicity 
and efficacy than traditional in vitro tumor models in conventional static culture well plates. 
In particular, in perfusion, paclitaxel showed a higher cytotoxicity, whereas 5-FU had fewer 
efficacies as compared to static culture 90. Recently, studies from our group have shown that  
culturing CRC cell lines in a perfused bioreactor system previously utilized for the culture of 
different mesenchymal cell types results in the development of tissue-like-structures 
efficiently mimicking phenotypes, gene expression profiles and drug resistance patterns 
observed in cell-line derived xenografts. 91. 
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3.4 Patient-derived tumor xenograft 
Patient-derived tumor xenograft (PDTX), developed injecting primary tumor cells into an 
immunodeficient mouse, have been used to predict drug response of individual patient tumors 
92. However, tumor uptake rate might be low (ranging from 30% to 60%) and tumor 
development might require a longer period of time. Also, obtaining a sufficient number of 
PDTX may require additional “passage” in into other recipient mice. During this time 
patient’s tumor might change the genetic characteristics93 and biological behavior 73. More 
importantly, PDTX cannot fully mimic the human CRC microenvironment. In fact, over time, 
the human stromal cells are replaced by the murine stroma, although the exact timing and 
replacement of human to with murine stromal cells remains unclear 94.  Despite these 
limitations, there are certain aspects of efficacy and toxicity that will always require 
evaluation in animal models prior to human clinical trials. In conclusion, despite PDTX 
represent an attractive system for CRC drug development, the increasing need for 
personalized medicine will require novel culture system able to more accurately mimic in 
vivo conditions. Moreover, preclinical studies that utilize the advantages of 3D culture can 
greatly improve the understanding of cancer biology, eliminate poor drug candidates, and, 
most promisingly, reveal new more physiologically-relevant targets that might have been 
missed in 2D screens. Establishing a 3D model system can save time and money by 
generating more significantly realistic results. 
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Figure I.7 - 2D and 3D primary cell cultures. ( adapted from Fatehullah et al, 2016 95)  
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CHAPTER II  
AIM OF THE STUDY 
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The limited response rate to therapies currently available for patients suffering from CRC 
urges the development of novel, more effective treatments. 
Accumulating evidence indicates that non-transformed cells within the TME also play key 
roles in the control of tumor progression and response to treatment. However, the possibility 
to assess their impact on tumor cell responsiveness to novel anti-cancer therapies is hampered 
by the lack of preclinical systems reliably mirroring the interaction between malignant and 
non-transformed cells. 
Previous studies from our group have addressed the suitability of a perfusion-based 
bioreactor, previously developed for engineering of cartilage, bone tissues 96,97 and for tumor 
engineering purposes91. Culture of CRC cells from established cell lines on a collagen 
scaffold under perfusion resulted in the formation of tumor tissue-like structures whose gene 
expression and, most importantly, drug sensitivity profiles, were more similar to those of in 
vivo developed tumors as compared to cells cultured as monolayers or in static 3D 
conditions91. 
Capitalizing on these data, during my PhD studies I have been exploiting the use of the 
perfusion-based bioreactor for in vitro culture of human primary CRC specimens. 
In particular, I have addressed the suitability of the perfusion-based bioreactor for: 
▪ The maintenance of the heterogeneity of CRC microenvironment as compared to static 
cultures 
▪ The assessment of drug responsiveness of primary CRC tissues 
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CHAPTER III  
MATERIALS AND METHODS 
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3.1 Tumor sample processing 
Human primary colorectal cancer specimens were obtained from consenting patients 
undergoing surgical treatment at the University Hospital Basel, St. Claraspital in Basel, and 
Ospedale Civico of Lugano, all in Switzerland. Use of human samples was approved by local 
ethical authorities (Ethikkommission Nordwest und Zentralschweiz, study protocol no 2014-
388). Clinico-pathological characteristics of tumor samples used are listed in Table III.1.  
Features Frequency n (%) 
   
Age Mean (range) 72 (49-87) 
   
Gender  Female 11 (58) 
 Male 8 (42) 
   
Tumor location  Left-sided 9 (47) 
 Right-sided 10 (53) 
   
Grade  G1 0 (0) 
 G2 14 (78) 
 G3 4 (22) 
   
pT stage  T1 1(5) 
 T2 5 (26) 
 T3 9 (47) 
 T4 4 (21) 
   
pN stage  N0 12 (63) 
 N1 5 (26) 
 N2 2 (11) 
   
Distant metastasis  Absent 16 (84) 
 Present 3 (16) 
     
* Information available for n=19/23 patients included in the study 
Table III.1. Clinical pathological characteristics of patients included in the study. * 
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Tumor specimens were sampled by experienced gastrointestinal pathologists from freshly 
resected cancer tissues based on macroscopical evaluation, and maintained in Custodiol HTK 
solution (Dr. Franz Köhler Chemie GmbH) at 4°C until used. To reduce the risk of 
contamination due to stool residues, specimens were rinsed in PBS before processing, and 
incubated in a 10% Octenisept (Schülke & Mayr AG) solution for 5 minutes. After additional 
washings in PBS, tumor specimens were fragmented in 2x2x2 mm chunks. Three randomized 
chunks from each sample were immediately embedded in Optimal cutting temperature 
compound (OCT, Leica Biosystem) and preserved at -80°C, as “Fresh” controls. Remaining 
fragments were weighted and used for cultures. 
3.2 Tumor specimen culture under static conditions 
Three randomized CRC fragments were placed into a culture plate (Sigma) in DMEM/F12 
(Gibco) supplemented with 5% pooled human AB serum (Blood Bank, University Hospital 
Basel), 2mM Glutamine (GlutaMAX-I, Gibco), 100M HEPES (Gibco), 1µg/mL Kanamycin 
sulphate (Gibco), 2.5µg/mL Amphotericin B (Sigma-Aldrich A9528), 20µg/mL Metronidazol 
(Braun), 60µg/mL Cefuroxim (Braun), 10µg/mL Ciproxine (Bayer Schering Pharma), 10µM 
N-Acetyl-Cysteine (Sigma-Aldrich), 20µM Nicotinamide (Sigma-Aldrich), 25ng/mL 
Epidermal Growth Factor (Stem Cell Technologies), 0.1µg/mL Prostaglandin E2 (Tocris 
Bioscience). Three days after, fragments were collected, weighted upon removal of superficial 
medium by absorbent tissues, and embedded in OCT for subsequent histomorphological 
evaluation. 
3.3 Tumor specimen culture in bioreactor under perfusion 
Two scaffold discs (8mm diameter x 3mm), made from a porous water insoluble partial 
hydrochloric acid salt of purified bovine corium collagen sponge, known as Ultrafoam 
Collagen Hemostat (Avitene, Bard), were soaked in culture medium for 1 h at 37°C. 
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Three randomized CRC fragments were placed between the discs in a sandwich-like 
configuration. The sandwich was assembled within a ring-shaped plastic holder closed on top 
and bottom by two EFTE nylon meshes (Fluorotex Sefar, 09-590/47) (Figure III.1).  
 
Figure III.1 - Schematic representation of the experimental design. Freshly resected CRC 
specimens were fragmented in 2x2x2 mm chunks. For perfused cultures, tumor fragments 
(n=3/bioreactor) were placed between two collagen type I discs within a ring-shaped holder, 
restrained by two grids on the top and bottom. The holder was then inserted in the bioreactor 
chamber and subjected to continuous alternate perfusion. For static cultures, tumor chunks 
(n=3/plate) were seeded in conventional culture plates. Perfused and static cultures were 
incubated at 37 °C for three days. 
The scaffold assembly was then placed into the perfusion chamber of a previously described 
perfusion-based bioreactor 98 (currently distributed as U-CUP by Cellec Biotek AG) and 
perfused with the same culture medium used for static cultures. Perfusion flow rate was set at 
0.3mL/min, corresponding to a superficial velocity of 100µm/sec 99, as previously used for the 
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generation of normal and tumor tissue-like constructs 91,98-101. In all experiments, a minimum 
of two bioreactors including a total of six tumor fragments per condition were used. At the 
end of the culture, fragments were collected, weighted upon removal of superficial medium 
by absorbent tissues, and embedded in OCT, for histomorphological evaluation. 
3.4 Histomorphological assessment and immunofluorescence 
Eight-micrometer cryosections were obtained from cryopreserved, OCT embedded, freshly 
resected tumor chunks, or from fragments maintained in static or perfusion-based cultures.  
For each specimen 10 sections were cut from ≥2 different levels of the entire tissue block. 
Slides were fixed with formalin 4% and stained with Hematoxylin and Eosin (H&E) or used 
for immunofluorescence (IF) analysis. 
Upon H&E staining, abundance of epithelial components of neoplastic tissues was semi-
quantitatively assessed by an experienced gastrointestinal pathologist, based on the evaluation 
of a minimum of two sections for each specimen and five regions of interest (ROI) per section 
at 40X magnification using Zeiss Axioskop 2 Plus microscope. 
In immunofluorescence studies, epithelial and stromal cells were identified upon staining with 
(Table III.2) anti-EpCAM mouse mAbs followed by Alexa Fluor 546-labelled goat anti-
mouse polyclonal antibodies,  and anti-Vimentin rabbit mAb followed by Alexa Fluor 488-
labelled goat anti-rabbit polyclonal antibodies. Tumor-infiltrating immune cells were 
identified by staining with anti-CD45-specific Alexa Fluor 488 labelled mouse mAb. To 
evaluate proliferating and apoptotic cells, tissue sections were stained with anti-Ki67 488-
labelled mAb or anti-cleaved Caspase 3 (cC3) rabbit polyclonal antibodies, followed by 
Alexa Fluor 488-labelled goat anti-rabbit polyclonal antibodies. Nuclei were counterstained 
by DAPI (Invitrogen). 
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Table III.2 - List of antibodies used in this study. 
Images were taken by using IX83 inverted microscope system (Olympus). Numbers of total 
nuclei or cells positive for Vimentin and  cC3 were analyzed using an automated image 
quantification program (see below), while the number of CD45 and Ki67+ cells were 
manually counted. For each specimen five ROI per section were analyzed. 
3.5 Image analysis 
The number of (Vimentin+) stromal and (cC3+) apoptotic cells were quantified using 
CellProfiler 2.1.1 102, an automated image analysis software which can accurately identify 
cells using advanced algorithms, and whose pipeline can be organized according to specific 
needs (Figure III.2). 
Images of the different components and the nuclei, stained as described above and taken using 
the IX83 inverted microscope system (Olympus) where collected using separated channels. 
The images where uploaded in CellProfiler and processed with a well-defined pipeline 
organized according to the following modules:. 
Specificity Clone Host Company Code Dilution 
EpCAM VU1D9 Mouse Cell Signaling 2929 1:100 
Alexa Fluor 546 Polyclonal Goat Invitrogen A-11030 1:100 
Vimentin D21H3 Rabbit Cell Signaling 5741 1:100 
Alexa Fluor 488 Polyclonal Goat Invitrogen A-11034 1:100 
CD45 488-labelled HI30 Mouse BioLegend 14-0459-
82 
1:100 
Ki67 488-labelled  EPR3610 Rabbit abcam ab92742 1:200 
Cleaved Caspase 3 Polyclonal Rabbit Cell Signaling 9661 1:100 
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Figure III.2 - CellProfiler interface and pipeline of the work. CellProfiler interface has a 
pipeline based on several modules that can be modulated according to specific needs. In this 
figure, the pipeline used for our analysis is depicted. The first module image math is used to 
subtract the background from the images. The following modules identified the nuclei and 
cells and finally the last modules calculate the percentage of the objects identified. 
• ImageMath - This module performed a subtraction of two different channels of the 
same image in order to remove the background. 
• Identify Primary object (nuclei) - This module, based on a three-step strategy, is 
used for identification of the nuclei in grayscale images that show bright objects on a 
dark background. Briefly, first the nuclei were identified based on the typical diameter 
range of 15, 100 pixels. Then, was determined whether an object was an individual 
nucleus or two or more clumped nuclei and the object edge was identified based on a 
thresholding method. Finally, identified objects are either discarded or merged 
together based on user-defined rules.  
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• Identify Secondary Objects - Cell cytoplasm identified based on the distance from 
the nuclei collected by the previous module. 
• Identify Primary object (Vimentin+, cC3+) - The two different channels 
corresponding to stromal and apoptotic cells were identified using the “identify 
primary object module”, as described above. The dimeter range in pixel is chosen 
between [1; 105 ]  pixels.                   
• The “Related objects” and “filtered objects” modules were used to identify the cells 
based on the overlap with the nuclei and filter them based on an intensity threshold. 
Those modules allow discriminating cells from non-specific background.  
• Export to Spread Sheet - Measurements were converted to character-delimited text 
formats and saved to the hard drive in one or several files. 
• Calculate Math - Calculate Math took measurements produced by the identification 
objects modules and calculated the percentage of positive cells. 
3.6 Assessment of functionality of immune and mesenchymal stromal cells 
To assess the functionality of tumor infiltrating lymphocytes, phytohaemagglutinin (PHA, 
1µg/mL, Remel Inc.) was added to the culture medium at the beginning of the culture. To 
evaluate viability and functions of mesenchymal stromal cells, human recombinant IL-17 
(10ng/mL, R&D Systems) was added to the culture medium in the last 24 hours of culture. To 
evaluate responsiveness to drug treatment, 5-FU (10µg/mL) was added to culture medium. 
After three days, culture media were collected and assessed for cytokine content by ELISA.  
IL-2, IFN-, and IL-6 release in culture media was assessed by using commercial IL-2 and 
IFN- ELISA kits (BD Biosciences), and Human IL-6 Instant ELISA (BioLegend), 
respectively, according to standard protocols. 
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3.7 Statistical analysis 
Statistical significance of observed differences was tested using Wilcoxon matched-pairs 
signed rank test. Two-sided p-values were considered significant at p values <0.05 (* p≤0.05; 
** p≤0.01).  Statistical analysis was performed using GraphPad Prism version 7.0c (GraphPad 
Software, La Jolla California USA, www.graphpad.com). 
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4.1 Culture under perfusion preserves the heterogeneity of CRC 
microenvironment 
Tumor fragments from freshly resected human CRC specimens were placed between two 
collagen scaffolds in a sandwich-like configuration and cultured under perfusion in a 
previously described bioreactor 91,98 up to three days, a time point used in previous studies 87 
to assess drug responsiveness on human CRC tissues (Figure III.1). Tissue valuable for 
subsequent analysis was recovered in 23 out of 23 samples. 
As static culture controls, in initial experiments tissue samples were embedded in sandwich-
scaffolds and maintained in bioreactors without perfusion. However, these culture conditions 
resulted in complete tissue loss, precluding subsequent analysis (data not shown). Therefore, 
as alternative static condition, tumor fragments were seeded in conventional culture plates 
(Figure III.1), a condition allowing the recovery of at least one tumor fragment out of three in 
all experiments performed (n=17). 
Tissue mass analysis performed before and after culture showed that perfused cultures 
preserved up to 75±8% of tissue weight, as compared to 31±16% only in static cultures 
(p=0.0078, Figure IV.1A). Accordingly, on histomorphological analysis, perfused tissues 
maintained higher tissue cellularity, as indicated by total nuclei counts, in comparison to static 
cultures (68±20% and 40±23%, respectively, p=0.02, Figure IV.1B). 
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Figure IV.1. Culture under perfusion preserves the heterogeneity of CRC micro-
environment. Tumor fragments derived from CRC specimens were weighted, and cultured in 
perfused bioreactors (Perf) or under static conditions (Stat), as described in Figure III.1. 
After three days, fragments were collected, weighted, and embedded in OCT for 
histomorphological evaluation. A. Weight of cultured tumor chunks is shown as percentage of 
that recorded prior to culture (Fresh). Mean ± SD (n=8, left panel) and individual values 
(right panel) are shown B. Cultured tissues were stained by DAPI and cell nuclei within five 
ROI per chunk, identified at 40X magnification, were counted using CellProfiler image 
analysis software. Cumulative data refer to absolute cell nuclei counts in fresh tissues, chunks 
cultured under perfusion, or chunks cultured under static conditions (left panel),  and cell 
nuclei counts in chunks cultured under perfusion, or static conditions as related to those of 
fresh tissues (right panel) (n=9). Data are expressed as mean ± SD.  
 Importantly, evaluation of tissue quality and composition showed that original architecture 
was partially maintained in CRC tissues cultured in the perfused bioreactor, whereas it was 
completely lost in non-perfused cultures (Figure IV.2).  
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Figure IV.2 – Assessment of TME components in CRC cultures. Fresh tissues (Fresh) or 
tissues cultured under perfusion (Perf) or static conditions (Stat) were subjected to H&E 
staining (left panels) or to IF analysis (middle and right panels), following stainings for 
EpCAM (red), vimentin (green), CD45 (green), and DAPI (blue). Images from a 
representative CRC sample were obtained at 20X magnification, scale bar 50 µm.  
In particular, in cultures under perfusion the epithelial component was only partially and not 
significantly reduced as compared to fresh tissues (35±14% versus 59±27%, respectively, p-
value>0.1). In contrast, tumor tissues cultured under static conditions displayed significantly 
reductions of epithelial cell fraction (10±13%, p=0.022 versus fresh tissues, p=0.016 versus 
perfused cultures) (Figure IV.3A). Notably, in four out of seven samples evaluated, the 
epithelial fraction was completely lost (Figure IV.3A). Numbers of mesenchymal stromal 
cells, as assessed upon vimentin staining, were also comparable in fresh tissues and tissues 
cultured under perfusion (out of five ROI:  604±376 and 465±227 positive cells, respectively, 
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p>0.3). However, they were significantly reduced in static cultures (128±102 positive cells), 
as compared to both fresh tissues and perfused cultures (p=0.008 and 0.016, respectively) 
(Figure IV.3B). Tumor infiltrating immune cells, identified as CD45+ cells, although being 
markedly reduced in both culture types, were still clearly detectable in perfused tissues (out of 
five ROI: 75±127 cells versus 173±145 in fresh tissues, p>0.05) whereas they were almost 
completely lost upon static culture (9±9, p=0.008 versus fresh tissues, p=0.054 versus 
perfused cultures, Figure IV.3C). 
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Figure IV.3 - Culture under perfusion preserves the heterogeneity of CRC 
microenvironment. A. CRC fresh tumor fragments or tissues cultured under perfusion or 
static conditions were processed and nuclei were stained and counted as detailed in Figure 
IV.2. Fresh tissues or tissues cultured under perfusion or static condition were subjected to 
H&E staining (A) or to IF analysis (B and C), following stainings for EpCAM, vimentin, 
CD45 and DAPI. Data refer to percentages of epithelial tissue scored based on H&E staining 
(A), or numbers of vimentin+ (B) or CD45+ cells (C) counted out of five ROI per chunk in 
individual fresh or cultured CRC samples. Statistical significance of differences observed was 
tested by Wilcoxon signed rank test (*p<0.05; **p<0.01). 
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These results indicated that short-term culture of primary tumor fragments under perfusion 
maintains heterogeneity of CRC microenvironment to significantly higher extents, as 
compared to static cultures. 
4.2 Perfused cultures better preserved viability and functionality of all CRC 
cellular components 
To further assess cell viability within cultured tissues, we evaluated proportions of 
proliferating or apoptotic cells, upon Ki67 or cC3 staining, respectively (Figure IV.4 and 
Figure IV.5). 
In perfused cultures, proliferation and apoptotic rates were comparable to those observed in 
fresh tissues (Ki67+ cells: 5±5% versus 6±4%; cC3+ cells: 7±7% versus 5±4 %, respectively, 
Figure IV.5A and B). In contrast, in static cultures, percentages of proliferating cells were 
significantly reduced (1±1%, p=0.004 versus both fresh and perfused tissues), whereas those 
of apoptotic cells were significantly increased (18±20, p=0.047 versus fresh tissues, Figure 
IV.5A and B). Therefore, tissues cultured under static conditions displayed markedly and 
significantly decreased Ki67/cC3 ratios (Figure IV.5C). 
Notably, in all conditions proliferating Ki67+cells were only detectable within the epithelial 
cell fraction. Thus, in tissues cultured under perfusion tumor cells are not only maintained in 
larger percentages but also in a more active state. 
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Figure IV.4 - Assessment of tumor cell viability in CRC cultures. CRC fragments freshly 
resected or cultured for three days in perfused bioreactors (Perf) or under static conditions 
(Stat), were analyzed by immunofluorescence upon staining for Ki67 (green), EpCAM (red), 
cC3 (green), and DAPI (blue). Representative images obtained at 20X magnification, scale 
bar 50 µm.  
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Figure IV.5 - Perfusion allows maintenance of viable and proliferating tumor cells. CRC 
fragments freshly resected or cultured for three days in perfused bioreactors (Perf) or under 
static conditions (Stat), were analyzed by immunofluorescence upon staining for Ki67, 
EpCAM cC3and DAPI. Percentages of Ki67+ (A, n=9), cC3+ cells (B, n=7) as related to 
numbers of total nuclei, and Ki67/cC3 ratios (C, n=7) with their individual values are shown. 
Cumulative data are expressed as mean ± SD. Statistical significance of observed differences 
was tested by Wilcoxon signed rank test (*p<0.05; **p<0.01). 
Next, we investigated functionality of mesenchymal stromal cells by evaluating their IL-6 
release, under steady state conditions or upon stimulation with IL17, a pro-inflammatory 
cytokine promoting IL-6 secretion by stromal cells 103. 
IL-6 release was clearly detectable in media from unstimulated bioreactor cultures. Most 
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importantly however, its amount was significantly increased upon IL-17 stimulation (p= 0.03, 
Figure IV.6A), thus indicating that stromal cells maintained in perfused cultures were viable 
and responsive to micro-environmental stimuli. We then assessed viability of tumor 
infiltrating immune cells cultured under perfusion. In particular, we tested whether infiltrating 
T lymphocytes, key players of anti-tumor immune responses 104,105, were still responsive to 
stimulation. Therefore, we measured release of IL-2 and IFN- T cell-derived cytokines, upon 
mitogenic stimulation. As expected, basal levels of T cell-derived cytokines, in particular of 
IL-2, largely varied between different samples (Figure IV.6B, right panel). Importantly 
however, they consistently increased upon stimulation (Figure IV.6B), thus suggesting that 
immune cells within CRC TME may be successfully activated during culture in bioreactors. 
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Figure IV.6 - Perfused cultures preserve functionality of tumor-associated stromal and 
immune cells. CRC fragments were cultured within perfused bioreactors for three days. A. In 
the last 24 hours of culture medium was supplemented with IL-17 (10ng/ml) or left 
unmodified (CTRL). IL-6 release was assessed by ELISA. Cumulative data expressed as mean 
± SD (left panel, n=6) and data from individual cultures (right panel) are shown. B. Cultures 
were performed in the absence (CTRL) or presence of PHA (1µg/ml). Release of IL-2 and 
IFN- in culture media was quantified by ELISA. Cumulative data (mean ± SD, n=6, left 
panels) and data from individual cultures (right panels) are reported. Statistical significance 
of observed differences was tested by Wilcoxon signed rank test (*p<0.05; **p<0.01). 
 
 
 
60 
4.3 Bioreactor-based cultures are amenable to test drug responsiveness of 
primary CRC tissues 
Finally, we evaluated the possibility to exploit bioreactor-based cultures to test responsiveness 
to drugs in primary CRC tissues. Fragments from six different samples were cultured under 
perfusion in the presence or absence of 5-FU, and proliferation and apoptosis rates were 
evaluated (Figure IV.7 and Figure IV.8). Following three days of treatment, an overall 
significant reduction in percentages of epithelial proliferating cells, and a significant increase 
in the fraction of apoptotic cells (Figure IV.8A and B) could be observed. Notably however, 
analysis of individual samples revealed more heterogeneous responses. In particular, two out 
of six samples showed negligible (P318) or partial (P345) inhibition of proliferation, whereas 
an additional sample (P343) displayed a cytostatic response only, with a dramatic reduction in 
proliferation, but no increase in the percentage of apoptotic cells (Figure IV.8C). 
Thus, bioreactor-based cultures appear to be suitable to assess patient-specific drug 
responsiveness in primary CRC within a short time frame. 
 
 
 
 
 
 
61 
 
Figure IV.7 - Evaluation of drug responsiveness of primary CRC tissues maintained under 
perfusion. CRC fragments were cultured within perfused bioreactors for 3 days in the 
absence (CTRL) or presence of 5-FU (10µg/ml). Representative IF analysis (magnification 
20X, scale bar 50 µm) upon Ki67 or cC3 (green), EpCAM (red), and DAPI (blue) staining. 
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Figure IV.8 - Bioreactor-based cultures are amenable to test drug responsiveness of 
primary CRC tissues. CRC fragments were cultured within perfused bioreactors for 3 days in 
the absence (CTRL) or presence of 5-FU (10µg/ml). A. Percentages of Ki67+ (left, n=6) or 
cC3+ cells (right, n=7). B. Percentages of Ki67+ and cC3+ cells in cultures supplemented 
with 5-FU relative to untreated tissues in individual samples. 
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CHAPTER V  
DISCUSSION 
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In the last decade, a major effort has addressed the development of tailored treatments 
targeting specific molecular alterations of cancer cells. However, in the era of “personalized 
medicine” a major challenge is still represented by the lack of adequate in vitro models 
predicting responsiveness to specific treatments, and guiding therapeutic decisions. This is 
particularly important for the management of CRC, a leading cause of cancer-related death, 
for which success rates of conventional chemotherapeutic regimens are limited, whereas 
alternative therapeutic approaches may be preferable. 
In this work, we have shown that culture of freshly resected human CRC specimens in a 
bioreactor under perfusion results in maintenance of viable whole tumor tissues, including 
cancer cells together with mesenchymal stromal cells and substantial fractions of immune 
cells, for a period reliably allowing assessment of tumor drug responsiveness. 
Tumor cells cultured under perfusion displayed an almost intact structure, as compared to the 
original tumors, and were viable and proliferating. In addition, stromal cells were maintained 
in proportions similar to those of original tumors and fully viable, as indicated by 
responsiveness to micro-environmental stimuli, such as IL-17. Furthermore, immune cells 
were also partially preserved, and were capable of releasing effector cytokines upon 
activation. 
In contrast, in cultures performed under static conditions, fewer viable tumor and stromal 
cells were preserved, whereas immune cells were completely lost. 
Importantly, perfusion-based cultures proved suitable for testing the sensitivity of primary 
tumor cells to chemotherapies of current use in CRC and revealed heterogeneous responses 
across individual samples. Thus, our system recapitulates key features of CRC TME and may 
allow the assessment of tumor response to treatment in a more reliable, patient-specific 
context. 
Established cell lines have long been recognized to substantially differ from primary tumor 
cells and to fail to mimic the complexity of tumor microenvironment 106. Therefore, 
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innovative culture systems relying on the use of primary tumor cells have been proposed. In 
particular, regarding CRC, multicellular tumor spheroids and organoids have been developed. 
Single CD133+ cells sorted from CRC specimens were shown to be able to expand in vitro in 
tridimensional spheroid-like structures 107. However, generation of CRC-derived spheres 
requires digestion of tumor tissues and pre-sorting of CD133+ cells.  Furthermore, sphere 
formation in CRC only occurs in a limited fraction of samples 108. 
Clevers and collaborators have pioneered the establishment of techniques reproducing in vitro 
“organoids” starting from cell clusters isolated from crypts derived from human normal or 
neoplastic intestinal epithelium 109. Organoid formation from primary CRC is highly 
reproducible and is suitable for high-throughput drug screening. Similarly, CRC tissue-
originated spheroids preserving cell-cell contact between primary tumor cells have been 
shown to expand with high success rates and to be amenable to drug testing 82,110. 
However, the formation of both spheroids and organoids relies on the generation of new 
tumor tissues starting from few putative stem cells. Thus, it requires long culture periods and 
the ability of newly generated structures to mirror original tumor tissue features is 
questionable. 
Most importantly, these culture systems, while allowing expansion of epithelial tumor cells, 
fail to preserve mesenchymal and immune cell TME components, which critically influence 
tumor growth and responsiveness to treatment in CRC. Thus, they do not allow the 
assessment of the responsiveness of cancerous cells to anti-cancer compounds within a 
context similar to that of in vivo tumors, and in particular to immunotherapeutic strategies. 
Short-term culture (up to 3 days) of CRC explants in tumor grade-matched matrix has been 
proposed as a platform for the prediction of tumor response to chemotherapy 87. This system 
certainly represents a major advance in primary tumor culture, inasmuch as it maintains the 
original tissue architecture and matrix protein components. Indeed, it has been shown to 
predict response to tumor cell-targeted therapies with high sensitivity and specificity. 
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However, it remains unclear whether this system, where cultures are performed under static 
conditions, also preserves tumor-associated mesenchymal cells and infiltrating immune cells, 
thus allowing testing of therapies targeting tumor-associated stroma. 
Our work shows that culture of human CRC tissues under perfusion preserves viable tumor 
cells for a period of time (3 days) comparable to that of the above described study. Most 
importantly, CRC-associated mesenchymal and immune cells, possibly modulating sensitivity 
of tumor cells to drugs, are also maintained in a viable and active state.  
The precise contribution of perfusion flow to maintenance of tumor and tumor-associated 
cells remains to be fully clarified. The continuous direct perfusion allows removal of cell 
waste products and maintenance of nutrient levels throughout the constructs, which is in turn 
promoting cellular proliferation and viability 91,99. Beyond reduction of mass transfer 
limitations, the flow-associated shear stress has been reported to facilitate the maintenance of 
stem cell status and prevent spontaneous differentiation 111. It may thus be speculated that 
cancer cells with stem cell-like features, including self-renewal ability, are preferentially 
maintained within perfused cultures due to the perfusion-driven mechanical signal, mimicking 
interstitial fluid flow.   
In conclusion, the aim of this work was the exploitation of a perfusion-based bioreactor for 
maintenance of human CRC tissues.  Thanks to its capacity to maintain TME heterogeneity, 
our system may allow personalized drug testing within a more physiological context. 
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CHAPTER VI  
FUTURE PERSPECTIVES 
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6.1 System's optimization and limitations 
A number of features of the culture condition still need to be optimized, including culture 
period, scaffold type, flow rate and clinical response. 
6.1.1 Culture period 
Indeed, our results showed that our system maintain alive up to three days all the cellular 
components of the native tissues. The possibility to extent the culture period to later time 
points will allow the test of tumor responsiveness to emerging immunotherapies that might 
required more time to be effective. In particular, we are now evaluating the possibility to 
extent the culture to later time points. In preliminary experiments CRC samples were cultured 
in the perfusion-based bioreactor for 3,5, 7 and 10 days.  Over time the tissue mass, in 
perfused cultures, appear to be maintained whereas it is progressively reduced in static 
conditions (Figure VI.1). 
 
Figure VI.1 - Time point evaluation, tissue mass. Tumor fragments derived from CRC 
specimens were weighted, and cultured in perfused bioreactors (Perf) or under static 
conditions (Stat), as described in Figure III.1. After respectively 3,5,7 and 10 days, fragments 
were collected, weighted, and embedded in OCT for histomorphological evaluation. Weight of 
cultured tumor chunks is shown as percentage of that recorded prior to culture (fresh). Mean 
± SD (n=4, upper panel) and individual values (lower panel) are shown. 
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Additional experiments need to be performed in order to address the quality and quantity of 
the tissue recovered from the culture in bioreactor and static conditions over time, and, most 
importantly, to evaluate whether all cellular TME components are also maintained. 
6.1.2 Scaffold Type 
Regarding the type of scaffold, all experiments have been performed so far on collagen type I 
scaffolds (Avitene ™ Ultrafoam ™). However, since tumor ECM is not only composed of 
collagen, but also of laminin, fibronectin and tenascin, in future experiment we intend to test 
different scaffold types, including Matrigel-coated scaffolds, decellularized small intestinal 
submucosa (SIS, Cook Biotech Inc.) and engineered stromal tissues obtained by ECM 
deposition and subsequent decellularization by deliberate cell‐apoptosis induction 112.   
In particular, in preliminary experiments we evaluated whether coating with Matrigel 
improves tumor cellular adhesion to the scaffold.  Indeed, we found that CRC cells lacking 
collagen binding receptors, such as HCT116 cells, adhere and proliferate to higher extents to 
Matrigel-coated as compared to uncoated scaffolds, and this phenomenon is dependent on 
Matrigel concentration. 
6.1.3 Flow rate 
Effects of flow rate on CRC cultures remain to be investigated. Indeed, capitalizing on results 
previously obtained in bone cell culture experiments, initial experiments were performed 
using a flow rate of 0.3 ml/minute. However how the flow rate can be translated into the shear 
stress experienced by the chunks in culture still need to be addressed. In future studies, we 
plan to use an approximate mathematical model to calculate the shear stress experienced by 
tumor chunks under different flow rates in order to understand which one better mimic the 
induced physiological shear stress. Moreover since the tumor stiffness has been established to 
play a key role in tumor progression,  in parallel, the stiffness of CRC chunks prior to or after 
 
 
 
70 
culture will be evaluated by atomic force microscope in order to understand if it mimics the 
physiological tumor stiffness.  
6.1.4 Clinical response 
In our study we did not planned to assess the ability of our system to predict patient-specific 
clinical response. In fact, the experiments were conducted on patient already treated by 
surgery thus tumor free and the tumor relapse can only be evaluated after 5 years. 
We envisage validating the system's ability to predict patient-specific clinical responses in the 
context of follow-up studies. 
6.2 Suitability of the perfusion-based bioreactor for the assessment of the 
tumor response to emerging stroma-targeted therapies 
Our culture system may also prove suitable for testing therapies whose efficacy is influenced 
by whole TME, such as drug-loaded nanoparticles 113 , or for emerging stroma-targeted 
therapies, including immunotherapies. 
6.2.1 Testing of novel nanoparticles-mediated drug delivery 
During my PhD studies I started to explore the suitability of bioreactor-based cultures for 
testing efficacy of  nanoparticles (NPs)-mediated  drug delivery.  
NP-mediated drug delivery is a novel promising therapeutic approach allowing achievement 
of high drug concentrations at the target site, while reducing toxic effects on normal tissues. A 
number of factors critically impact NP distribution and efficacy of drug delivery. First, the 
specificity of tumor targeting is critical, since receptors targeted by NPs can often be 
expressed, although at low levels, also on normal cells 114. NP surface charge also plays a 
major role. Indeed the ECM is composed of collagen fibers and negatively charged 
glycosaminoglycans. Therefore, positively charged NPs are retained in the ECM, whereas 
negatively charged NPs can more easily distribute throughout the tissues 115. Moreover, 
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another important aspect is NP stability which within cancer tissues may be affected by 
enzymatic degradation. 
However, in vitro models capable of recapitulating the complexity of the TME that might 
provide insights on physicochemical parameters influencing effectiveness of nanoparticles as 
drug delivery systems are still missing.  
Several nanocarrier systems for cancer treatment have been developed 116 and many of them 
are under clinical investigation 117. In particular, in CRC, poly(ethylene glycol) (PEG) NPs 
targeting the tumor marker carcinoembryonic antigen (CEA) have been shown to successfully 
improve tumor localization in vitro and in vivo, in a mouse model 118. Moreover, treatment of 
CRC cell lines with solid lipid nanoparticles allowing simultaneous delivery of two distinct 
anticancer compounds, has been shown to result in enhanced mortality of tumor cells 119. 
Furthermore, poly(γ-benzyl-L-glutamate) (PBLG) - PEG NPs, loaded with 5-FU, have shown 
sustained drug release, prolonged drug half-life, and increased tissue appetency in CRC cell 
lines and CRC xenografts 120. Human serum albumin (HSA) NPs conjugated with 5-
fluorouracil have been showed to increase drug delivery and cytotoxicity to cells from 
established cell lines cancer HT-29 cells121. Moreover, glycogen nanoparticles have been 
recently investigated for the construction of in vivo imaging nanoagents 122. Glycogen is a 
biocompatible polymer, which thanks to its chemical structure cannot degrade in the 
bloodstream and, due its high molecular weight, is not directly eliminated by kidney 123. In 
contrast, after internalization into cells, it is rapidly degraded into D-glucose. Notably, 
glycogen is internalized into tumor cells, including CRC cells, at higher levels as compared to 
normal cells 124. Therefore, the use of glycogen-based nanocarriers may be exploited for 
anticancer drug delivery.  
During my PhD studies, I visited the Nanostructured Interfaces and Materials Science Group 
(NIMS) at the Chemical Engineering department of the University of Melbourne led by 
Professor Frank Caruso, who has pioneered the development of new generation particle 
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systems with engineered properties for targeted anti-cancer drug deliver. His group has 
previously developed bio-functionalized polymeric nanoparticles conjugated with an antibody 
specific for the A33 antigen, expressed on human CRC cells 125,126 and lactosylated glycogen 
NPs for targeting prostate cancer cells 127. Moreover, the group has developed a ultrasonic 
cavitation system  to form in a short time HSA NPs with stable size and uniform distribution 
128. In the context of collaborative studies, we have started to evaluate the suitability of our 
bioreactor-based system for testing the efficacy of glycogen- and HSA-NP-mediated drug 
delivery.  Our preliminary experiment showed that the HSA NPs characterized by high 
biocompatibility, stability, negatively charged and with 150nm diameters, can be efficiently 
perfused in a engineered tumor tissue able to mimic the interaction between malignant and 
non-transformed cells of the TME (Figue VI.2).  
 
Figure VI.2 - HSA NPs can be efficiently perfused in a engineered TME. HSA NPs (150 
nm) were perfused for 48 hrs in a engineered TME using the perfusion-based bioreactor. The 
model has been obtained by culturing HT29 CRC tumor cells and 3T3 fibroblasts for 3 weeks 
on a collagen type-I scaffold (Ultrafoam) in the perfusion-based bioreactor.  The HSA NPs 
were 488-labeled (green). The scaffold was collected and embedded in OCT for 
histomorphological evaluation and the cell membranes were stained for wheat germ 
agglutinin (WGA) (red). Images were taken using a confocal at 60X magnification. 
20 µm 20 µm 
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Moreover, preliminary experiments showed that glycogen-based NPs (80-10nm) can be 
efficiently perfused in primary CRC tissues using the perfusion-based bioreactor (Figure 
VI.3). 
 
Figure VI.3 - HSA NPs can be efficiently perfused in primary CRC tissues. Scanning 
electron microscopy (SEM) images of of primary CRC tissues cultured for 48 hrs in the 
perfusion-based bioreactor in the presence of glycogen-based NPs. 
6.2.2 Testing of emerging stroma-targeted therapies 
Future studies are warranted to investigate the use of perfusion-based cultures of primary 
CRC tissues as potential platform for emerging stroma-targeted therapies including TGF-
 blockers 129, BsAbs 130, or immunological checkpoint inhibitors 131. 
The TGF-β pathway contributes to generate a favorable microenvironment for tumor growth 
and metastasis throughout all the steps of carcinogenesis and so, targeting the TGF-β pathway 
in cancer may be considered as a primarily microenvironment-targeted strategy. Several 
pharmacological approaches to block TGF-β signaling, including monoclonal antibodies, and 
small molecule inhibitors, have been developed and are currently being tested in clinical trials 
for different cancer types, including CRC. However, there are still potential limitations and 
risks of TGF-β targeted therapy including cardiotoxicity 132. Thus, caution must be given as to 
how much therapy and when would be beneficial or how much toxicity will be induced by 
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chronically administered therapy133. Therefore, systems able to predict the in vitro clinical 
response to TGF-β targeted therapy are urgently needed. 
BsAbs are a promising strategy to fight cancer by directly redirecting immune cells to tumor 
cells. In CRC, many BsAbs are now in various phases of clinical development such as the 
anti-CD3 +-EpCAM (MT110, BiTE, Amgen) 134. 
Immune checkpoint inhibitors, such as the anti-PD-1 antibody, found recent success in 
metastatic CRC with deficient mismatch repair system. Major challenges are ahead in order to 
determine how, when and which CRC patients might benefit from the use of these immune 
checkpoint inhibitors. 
Complementary studies from our group focusing on breast cancer have recently shown that 
the perfusion-based bioreactor system can be efficiently used for the ex-vivo assessment of 
drug response to anti-programmed-death-Ligand (PD-L)-1 and anti-cytotoxic T lymphocyte-
associated protein (CTLA)-4 antibodies on breast cancer primary tissue135. However, the 
culture conditions for tissues more difficult to maintain in vitro, such as CRC tissues, needs to 
be optimized.  
In conclusion, novel treatments targeting non-neoplastic cells are being developed for CRC, 
but there are not yet systems able to predict the personal clinical response. The optimization 
of our perfused-based bioreactor 3D system may offer the possibility to test the efficacy of 
these reagents on primary tumor-associated stroma and in a patient-specific context, thus 
possibly paving the way towards personalized therapeutic approaches.  
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1. Introduction
Colorectal cancer (CRC) is a leading 
cause of cancer-related death worldwide.[1] 
Whereas surgery represents the first 
therapeutic option for early stage disease, 
in more advanced stages the treatment 
includes chemotherapy, generally based 
on the administration of 5-fluorouracil 
(5-FU), in association with oxaliplatin 
(FOLFOX) or irinotecan (FOLFIRI). How-
ever, these chemotherapy protocols are 
characterized by low response rates, usually 
not exceeding 20% of treated patients.[2]
The development of novel, more effec-
tive therapies is hampered by the lack of 
culture systems adequately mimicking 
the architectural and cellular complexity 
of the tumor microenvironment (TME). 
Nontransformed cells within the TME, 
including so-called tumor-associated 
mesenchymal stromal cells and tumor-
infiltrating immune cells, have been 
 recognized to profoundly affect response 
Colorectal cancer (CRC) is a leading cause of cancer-related death. Conven-
tional chemotherapeutic regimens have limited success rates, and a major 
challenge for the development of novel therapies is the lack of adequate in 
vitro models. Nonmalignant mesenchymal and immune cells of the tumor 
microenvironment (TME) are known to critically affect CRC progression and 
drug responsiveness. However, tumor drug sensitivity is still evaluated on 
systems, such as cell monolayers, spheroids, or tumor xenografts, which 
typically neglect the original TME. Here, it is investigated whether a bioreactor-
based 3D culture system can preserve the main TME cellular components in 
primary CRC samples. Freshly excised CRC fragments are inserted between 
two collagen scaffolds in a “sandwich-like” format and cultured under static or 
perfused conditions up to 3 d. Perfused cultures maintain tumor tissue archi-
tecture and densities of proliferating tumor cells to significantly higher extents 
than static cultures. Stromal and immune cells are also preserved and fully 
viable, as indicated by their responsiveness to microenvironmental stimuli. 
Importantly, perfusion-based cultures prove suitable for testing the sensitivity 
of primary tumor cells to chemotherapies currently in use for CRC. Perfusion-
based culture of primary CRC specimens recapitulates TME key features and 
may allow assessment of tumor drug response in a patient-specific context.
Dr. M. G. Muraro, Dr. C. Hirt, Dr. V. Governa, Prof. G. C. Spagnoli
Oncology Surgery
Department of Biomedicine
University Hospital Basel
University of Basel
Basel 4031, Switzerland
Dr. S. Däster, Dr. S. D. Soysal, Dr. R. A. Droeser, Dr. R. Mechera,  
Prof. D. Oertli
Department of Surgery
University Hospital of Basel
Basel 4031, Switzerland
Prof. R. Rosso
Department of Surgery
Canton Hospital Lugano
Lugano 6900, Switzerland
Dr. M. Bolli
Department of Surgery
Claraspital, Basel 4058, Switzerland
3D Culture Systems
Dr. C. Manfredonia, Dr. V. Mele, Dr. V. Governa, Prof. G. Iezzi
Cancer Immunotherapy
Department of Biomedicine
University Hospital Basel
University of Basel
Basel 4031, Switzerland
E-mail: giandomenica.iezzi@eoc.ch
Dr. C. Manfredonia, Dr. M. G. Muraro, Dr. C. Hirt,  
Dr. A. Papadimitropoulos, Prof. I. Martin
Tissue Engineering
Department of Biomedicine
University Hospital Basel
University of Basel
Basel 4031, Switzerland
E-mail: ivan.martin@usb.ch
The ORCID identification number(s) for the author(s) of this article 
can be found under https://doi.org/10.1002/adbi.201800300.
Adv. Biosys. 2019, 3, 1800300
www.adv-biosys.comwww.advancedsciencenews.com
1800300 (2 of 11) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
to treatment and tumor clinical outcome.[3–5] Indeed, mesen-
chymal-related signatures have been found to predict poor 
clinical outcome[6,7] and relapse upon therapy.[8] Furthermore, 
CRC-derived stromal cells have been shown to promote chem-
oresistance of CRC cells to 5-FU and oxaliplatin in vitro.[9]
In contrast, CRC-infiltrating immune cells, and in par-
ticular CD8+ T lymphocytes and T-helper 1 cells, have been 
recognized to predict improved prognosis irrespective of tumor 
stage.[10] Underlying mechanisms are still largely unclear. T 
lymphocytes might kill tumor cells upon recognition of tumor-
associated (neo)-antigens.[11] Furthermore, defined T cell sub-
sets may be required for a full elicitation of chemotherapy 
effectiveness, as observed in mouse models of lung and breast 
cancer.[12] Finally, immune cells expressing Fc fragment recep-
tors, including NK and myeloid cells, might contribute to ther-
apeutic efficacy of growth factor receptor-specific monoclonal 
antibodies (mAbs) through antibody-dependent cell cytotoxicity 
(ADCC).[13]
Despite this evidence, drug screening is presently largely 
based on the use of established cell lines cultured in 2D tumor 
cell monolayers. More recently, multicellular tumor spheroids 
from cell lines[14] or primary tumor cells[15,16] and organoids 
from primary CRC tissues[17] have been shown to mimic mor-
phological and biochemical features of in vivo tumors and have 
been proposed to assess efficacy of novel compounds.[14,18] 
However, these systems still lack the interaction between tumor 
cells and nontransformed components of cancer tissues.[19] 
Improved spheroid-based cultures, also including stromal 
and endothelial cells, have been recently proposed, but, so far, 
only for culture of tumor cells derived from established cell 
lines.[20–22]
Alternatively, tumor xenografts, generated upon injection of 
cell lines in immunodeficient mice, and in particular patient 
derived xenograft (PDX) generated upon injection or implan-
tation of primary tumor cells, are also used. PDXs retain to 
remarkable extents biological, histological, genomic, gene, 
and biomarker expression profiles of their tumor of origin.[23] 
However, they lack human stromal and immune cells, which 
are rapidly replaced by murine cells.[24] Thus, the establishment 
of new technologies reliably allowing the maintenance of the 
whole human TME is critically required.
In the last few years, perfusion-based cell cultures have 
demonstrated a unique ability to promote generation of tissue 
constructs displaying biological and structural characteristics 
comparable with those of primary tissues.[25,26] Previous studies 
from our group have addressed the suitability of a perfused bio-
reactor for tumor engineering purposes. Culture of CRC cells 
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from established cell lines on collagen scaffold in this culture 
system, resulted in formation of tumor tissue-like structures 
displaying structural, molecular and drug sensitivity profiles 
similar to those of tissues generated in xenografts.[27] More 
recently, this perfused bioreactor has proved helpful for mid-
term culture of human breast cancer tissues.[28] However, its 
suitability, for tumor types more difficult to culture in vitro, 
such as CRC,[29] has not been tested yet.
Capitalizing on these data, in this work we have investigated 
the suitability of perfusion-based culture for the maintenance 
of the main cellular components of the TME of human primary 
CRC.
2. Results
2.1. Culture under Perfusion Preserves the Heterogeneity  
of CRC Microenvironment
Tumor fragments from freshly resected human CRC specimens 
were placed between two collagen scaffolds in a sandwich-like 
configuration and cultured under perfusion in a previously 
described bioreactor[27,30] up to 3 d, a time point used in pre-
vious studies[31] to assess drug responsiveness on human CRC 
tissues (Figure 1). Tissue valuable for subsequent analysis was 
recovered in 23 out of 23 samples.
As static culture controls, in initial experiments tissue sam-
ples were embedded in sandwich scaffolds and maintained in 
bioreactors without perfusion. However, these culture condi-
tions resulted in complete tissue loss, precluding subsequent 
analysis (data not shown). Therefore, as alternative static con-
dition, tumor fragments were seeded in conventional culture 
plates (Figure 1), a condition allowing the recovery of at least 
one tumor fragment out of three in all experiments performed 
(n = 17).
Tissue mass analysis performed before and after culture 
showed that perfused cultures preserved up to 75 ± 8% of tissue 
weight, compared to 31 ± 16% only in static cultures (p = 0.078, 
Figure 2A). Accordingly, on histomorphological analysis, per-
fused tissues maintained higher tissue cellularity, as indicated 
by total nuclei counts, in comparison to static cultures (68 ± 20 
and 40 ± 23%, respectively, p = 0.02, Figure 2B and Figure S1A, 
Supporting Information).
Importantly, evaluation of tissue quality and composition 
showed that original architecture was partially maintained in 
CRC tissues cultured in the perfused bioreactor, whereas it was 
completely lost in nonperfused cultures (Figure 2C). In par-
ticular, in cultures under perfusion the epithelial component 
was only partially and not significantly reduced as compared to 
fresh tissues (35 ± 14 vs 59 ± 27%, respectively, p-value > 0.1). 
In contrast, tumor tissues cultured under static conditions 
displayed significant reductions of epithelial cell fraction 
(10 ± 13%, p = 0.022 vs fresh tissues, p = 0.016 vs perfused cul-
tures) (Figure 2D). Notably, in four out of seven samples evalu-
ated, the epithelial fraction was completely lost (Figure S1B, 
Supporting Information). Numbers of mesenchymal stromal 
cells, as assessed upon vimentin staining, were also compa-
rable in fresh tissues and tissues cultured under perfusion (out 
of five ROI: 604 ± 376 and 465 ± 227 positive cells, respectively, 
Adv. Biosys. 2019, 3, 1800300
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p > 0.3). However, they were significantly reduced in static 
cultures (128 ± 102 positive cells), as compared to both fresh 
tissues and perfused cultures (p = 0.008 and 0.016, respec-
tively) (Figure 2E and Figure S1B, Supporting Information). 
Accordingly, tumor/stroma ratios were more strongly reduced 
upon static than perfused cultures (Figure S1C, Supporting 
Information).
Tumor-infiltrating immune cells, identified as CD45+ cells, 
although being markedly reduced in both culture types, were 
still clearly detectable in perfused tissues (out of five ROI: 
75 ± 127 cells vs 173 ± 145 in fresh tissues, p > 0.05), whereas 
they were almost completely lost upon static culture (9 ± 9, 
p = 0.008 vs fresh tissues, p = 0.054 vs perfused cultures, 
Figure 2F and Figure S1B, Supporting Information). Char-
acterization of immune cell subsets (Figure S2, Supporting 
Information) revealed that proportions of T lymphocytes 
(CD3+) were comparable in fresh tissues and perfused cul-
tures (26.51 ± 18.3 vs 23.8 ± 13.6% of total CD45+ cells), 
whereas they were significantly reduced in static cultures 
(2.3 ± 3%, p vs fresh = 0.02). Few B lymphocytes (CD19+) were 
detected in fresh CRC tissues (7.3 ± 8.4% of CD45+ cells). 
Upon culture under perfusion they were markedly reduced 
but still detectable (1.7 ± 2.1% p = n.s.), whereas upon static 
cultures they were completely lost. Finally, macrophages 
(CD64+) were detected in similar proportions in all culture 
conditions (6.6 ± 12.2 in fresh tissues, 7.3 ± 6.6 in perfused 
culture, 5.6 ± 6.5 in static cultures).
Endothelial cells, as assessed by CD31 expression, were pre-
served in both culture conditions in amounts comparable to 
those found in fresh tissues (Figure S3, Supporting Informa-
tion). Finally, when we evaluated distribution of collagen, one 
of major components of CRC extracellular matrix,[31] we did not 
observe major differences between fresh and cultured tissues 
(Figure S4, Supporting Information).
These results cumulatively indicated that short-term culture 
of primary tumor fragments under perfusion maintains het-
erogeneity of CRC cellular components to significantly higher 
extents, as compared to static cultures.
2.2. Perfused Cultures Better Preserved Viability  
and Functionality of All CRC Cellular Components
To further assess cell viability within cultured tissues, we evalu-
ated proportions of proliferating or apoptotic cells, upon Ki67 or 
cC3 staining, respectively (Figure 3 and Figure S5, Supporting 
Information). In perfused cultures, proliferation and apop-
totic rates were comparable to those observed in fresh tissues 
(Ki67+ cells: 5 ± 5% vs 6 ± 4%; cC3+ cells: 7 ± 7% vs 5 ± 4%, respec-
tively, Figure 3B,C and Figure S5, Supporting Information). 
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Figure 1. Schematic representation of the experimental design. Freshly resected CRC specimens were fragmented in 2 × 2 × 2 mm chunks. For perfused 
cultures, tumor fragments (n = 3/bioreactor) were placed between two collagen type I discs within a ring-shaped holder, restrained by two grids on the 
top and bottom. The holder was then inserted in the bioreactor chamber and subjected to continuous alternate perfusion. For static cultures, tumor 
chunks (n = 3/plate) were seeded in conventional culture plates. Perfused and static cultures were incubated at 37 °C for 3 d.
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Figure 2. Culture under perfusion preserves the heterogeneity of CRC microenvironment. Tumor fragments derived from CRC specimens were weighted 
and cultured in perfused bioreactors (Perf) or under static conditions (Stat), as described in Figure 1. After 3 d, fragments were collected, weighted, 
and embedded in OCT for histomorphological evaluation. A) Weight of cultured tumor chunks is shown as percentage of that recorded prior to culture 
(fresh). Mean ± SD (n = 8, left panel) and individual values (right panel) are shown. B) Cultured tissues were stained by DAPI and cell nuclei within 
five ROI per chunk, identified at 40× magnification, were counted using CellProfiler image analysis software. Cumulative data refer to cell nuclei counts 
in chunks cultured under perfusion or static conditions as related to those of fresh tissues (n = 9). Data are expressed as mean ± SD. C) Fresh tissues 
or tissues cultured under perfusion or static conditions were subjected to H&E staining (left panels) or to IF analysis (middle and right panels), fol-
lowing stainings for EpCAM (red), vimentin (green), CD45 (green), and DAPI (blue). Images from a representative CRC sample were obtained at 20× 
magnification, scale bar 50 µm. D) Percentages of epithelial tissue scored in fresh or cultured tissues, based on H&E staining. Cumulative data are 
expressed as mean ± SD (n = 7). E,F) Numbers of vimentin+ or CD45+ cells counted out of five ROI per chunk are shown (n = 8). Statistical significance 
of differences observed was tested by Wilcoxon signed rank test (*p < 0.05; **p < 0.01).
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Figure 3. Perfusion allows maintenance of viable and proliferating tumor cells. CRC fragments freshly resected or cultured for 3 d in perfused bioreac-
tors (Perf) or under static conditions (Stat) were analyzed by immunofluorescence upon staining for Ki67 (green), EpCAM (red), cC3 (green), and 
DAPI (blue). Five ROI per chunks were identified at 40× magnification, and total cell nuclei were counted using CellProfiler image analysis software. 
A) Representative images obtained at 20× magnification, scale bar 50 µm. B–D) Percentages of Ki67+ (n = 9) and cC3+ cells (n = 7), as related to 
numbers of total nuclei, and Ki67/cC3 ratios (n = 7) are shown. Cumulative data are expressed as mean ± SD. Statistical significance of observed 
differences was tested by Wilcoxon signed rank test (*p < 0.05; **p < 0.01).
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In contrast, in static cultures, percentages of proliferating cells 
were significantly reduced (1 ± 1%, p = 0.004 vs both fresh 
and perfused tissues), whereas those of apoptotic cells were 
significantly increased (18 ± 20%, p = 0.047 vs fresh tissues, 
Figure 3B,C and Figure S5, Supporting Information). There-
fore, tissues cultured under static conditions displayed mark-
edly and significantly decreased Ki67/cC3 ratios (Figure 3D and 
Figure S5, Supporting Information).
Notably, in all conditions Ki67 positivity was only detected 
within epithelial tumor cells. Thus, the perfusion allowed main-
tenance of larger numbers of viable and proliferating tumor 
cells as compared to static conditions.
Next, we investigated functionality of mesenchymal 
stromal cells by evaluating their IL-6 release, under 
steady-state conditions or upon stimulation with IL17, a pro-
inflammatory cytokine promoting IL-6 secretion by stromal 
cells.[32]
IL-6 release was clearly detectable in media from unstim-
ulated bioreactor cultures. Most importantly, however, its 
amount was significantly increased upon IL-17 stimulation 
(p = 0.03, Figure 4A and Figure S6A, Supporting Informa-
tion), thus indicating that stromal cells maintained in perfused 
cultures were viable and responsive to microenvironmental 
stimuli.
We then assessed viability of tumor-infiltrating immune 
cells cultured under perfusion. In particular, we tested whether 
infiltrating T lymphocytes, key players of antitumor immune 
responses,[11,33] were still responsive to stimulation. There-
fore, we measured release of IL-2 and IFN-γ T cell-derived 
cytokines, upon mitogenic stimulation. As expected, basal levels 
of T cell-derived cytokines, in particular of IL-2, largely varied 
between different samples (Figure S6B, Supporting Informa-
tion). Importantly, however, they consistently increased upon 
stimulation (Figure 4B), thus suggesting that immune cells 
within CRC TME may be successfully activated during culture 
in bioreactors.
2.3. Bioreactor-Based Cultures Are Amenable to Test Drug 
Responsiveness of Primary CRC Tissues
Finally, we evaluated the possibility to exploit bioreactor-based 
cultures to test responsiveness to drugs in primary CRC tis-
sues. Fragments from six different samples were cultured 
under perfusion in the presence or absence of 5-FU, and 
proliferation and apoptosis rates were evaluated (Figure 5). 
Following 3 d of treatment, an overall significant reduction in 
percentages of epithelial proliferating cells and a significant 
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Figure 4. Perfused cultures preserve functionality of tumor-associated 
stromal and immune cells. CRC fragments were cultured within perfused 
bioreactors for 3 d. A. In the last 24 h of culture, medium was supple-
mented with IL-17 (10 ng mL−1) or left unmodified (CTRL). IL-6 release was 
assessed by ELISA. Cumulative data are expressed as mean ± SD (n = 6). 
B) Cultures were performed in the absence (CTRL) or presence of 
PHA (1 µg mL−1). Release of IL-2 and IFN-γ in culture media was 
quantified by ELISA. Cumulative data are expressed as mean ± SD 
(n = 6) (*p < 0.05).
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increase in the fraction of apoptotic cells (Figure 5A,B) could 
be observed. Notably however, analysis of individual samples 
revealed more heterogeneous responses. In particular, two 
out of six samples showed negligible (P318) or partial (P345) 
inhibition of proliferation, whereas an additional sample (P343) 
displayed a cytostatic response only, with a dramatic reduction 
in proliferation but no increase in the percentage of apoptotic 
cells (Figure 5C).
Adv. Biosys. 2019, 3, 1800300
Figure 5. Bioreactor-based cultures are amenable to test drug responsiveness of primary CRC tissues. CRC fragments were cultured within perfused 
bioreactors for 3 d in the absence (CTRL) or presence of 5-FU (10 µg mL−1). A) Representative IF analysis (magnification 20×, scale bar 50 µm) upon 
Ki67 or cC3 (green), EpCAM (red), and DAPI (blue) staining. B) Percentages of Ki67+ (left, n = 6) or cC3+ cells (right, n = 7). C) Percentages of Ki67+ 
and cC3+ cells in cultures supplemented with 5-FU relative to untreated tissues in individual samples (*p < 0.05).
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Thus, bioreactor-based cultures appear to be suitable to 
assess patient-specific drug responsiveness in primary CRC 
within a short time frame.
3. Discussion
In the last decade, nontransformed cells of the TME have been 
recognized to heavily impact on tumor drug responsiveness 
and clinical outcome. However, in vitro models currently 
used for drug development do not take into account tumor–
stromal cell interactions, thus precluding on the one hand 
to assess the role of nonmalignant cells in tumor drug 
resistance and on the other to test novel stroma-targeted ther-
apies. This is particularly important for the management of 
CRC, a leading cause of cancer-related death, for which suc-
cess rates of conventional chemotherapeutic regimens are 
limited, whereas alternative therapeutic approaches may be 
preferable.
In this work, we have shown that culture of freshly resected 
human CRC specimens in a bioreactor under perfusion results 
in maintenance of viable whole tumor tissues, including cancer 
cells together with mesenchymal stromal cells and substantial 
fractions of immune cells, for a period of time reliably allowing 
assessment of tumor drug responsiveness.
Tumor cells cultured under perfusion displayed an almost 
intact structure, as compared to the original tumors, and were 
viable and proliferating. In addition, stromal cells were main-
tained in proportions similar to those of original tumors and 
fully viable, as indicated by responsiveness to microenviron-
mental stimuli, such as IL-17. Furthermore, immune cells were 
also partially preserved and were capable of releasing effector 
cytokines upon activation.
In contrast, in cultures performed under static conditions, 
fewer viable tumor and stromal cells were preserved, whereas 
immune cells were completely lost.
Importantly, perfusion-based cultures proved suitable for 
testing the sensitivity of primary tumor cells to chemotherapies 
of current use in CRC and revealed heterogeneous responses 
across individual samples. Thus, our system recapitulates key 
features of CRC TME and may allow the assessment of tumor 
response to treatment in a more reliable, patient-specific context.
Established cell lines have long been recognized to substan-
tially differ from primary tumor cells and to fail to mimic the 
complexity of tumor microenvironment.[34] Therefore, innova-
tive culture systems relying on the use of primary tumor cells 
have been proposed. In particular, regarding CRC, multicellular 
tumor spheroids and organoids have been developed. Single 
CD133+ cells sorted from CRC specimens were shown to be 
able to expand in vitro in tridimensional spheroid-like struc-
tures.[15] However, generation of CRC-derived spheres requires 
digestion of tumor tissues and presorting of CD133+ cells. Fur-
thermore, sphere formation in CRC only occurs in a limited 
fraction of samples.[35]
Clevers and collaborators have pioneered the establishment 
of techniques reproducing in vitro “organoids” starting from 
cell clusters isolated from crypts derived from human normal 
or neoplastic intestinal epithelium.[17] Organoid formation 
from primary CRC is highly reproducible and is suitable for 
high-throughput drug screening. Similarly, CRC tissue-orig-
inated spheroids preserving cell–cell contact between primary 
tumor cells have been shown to expand with high success rates 
and to be amenable to drug testing.[16,18]
However, the formation of both spheroids and organoids 
relies on the generation of new tumor tissues starting from 
few putative stem cells. Thus, it requires long culture periods, 
and the ability of newly generated structures to mirror original 
tumor tissue features is questionable.
Most importantly, these culture systems, while allowing 
expansion of epithelial tumor cells, fail to preserve mesen-
chymal and immune cell TME components, which critically 
influence tumor growth and responsiveness to treatment in 
CRC. Thus, they do not allow the assessment of the respon-
siveness of cancerous cells to anticancer compounds within a 
context similar to that of in vivo tumors and, in particular, to 
immunotherapeutic strategies.
Short-term culture (up to 3 d) of CRC explants in tumor 
grade-matched matrix has been proposed as a platform for the 
prediction of tumor response to chemotherapy.[31] This system 
certainly represents a major advance in primary tumor culture, 
inasmuch as it maintains the original tissue architecture and 
matrix protein components. Indeed, it has been shown to pre-
dict response to tumor cell-targeted therapies with high sensi-
tivity and specificity. However, it remains unclear whether this 
system, where cultures are performed under static conditions, 
also preserves tumor-associated mesenchymal cells and infil-
trating immune cells, thus allowing testing of therapies tar-
geting tumor-associated stroma.
Our work shows that culture of human CRC tissues under 
perfusion preserves viable tumor cells for a period of time 
(3 d) comparable to that of the above described study. Most 
importantly, CRC-associated mesenchymal and immune 
cells, possibly modulating sensitivity of tumor cells to drugs, 
are also maintained in a viable and active state. On the other 
hand, however, the composition of tumor matrix, also pos-
sibly influencing CRC survival and drug responsiveness,[36–38] 
could not be properly assessed in our system. Indeed, 
although collagen distribution in perfused cultures appeared 
to be comparable to that of fresh tissues, a proper quantifica-
tion of matrix components could not be achieved, due to lim-
ited tissue availability. We envisage to perform a comparative 
proteomic analysis between fresh and cultured tissues, either 
under static or perfused conditions, in the context of follow-
up studies.
The precise contribution of perfusion flow to maintenance 
of tumor and tumor-associated cells remains to be fully clari-
fied. The continuous direct perfusion allows removal of cell 
waste products and maintenance of nutrient levels throughout 
the constructs, which is in turn promoting cellular proliferation 
and viability.[27,39] Conversely, in static cultures, lack of oxygen 
and nutrients results in extensive cell necrosis, ultimately 
leading to proteolytic phenomena. This likely accounts for the 
dramatic tissue loss observed upon static cultures. Beyond 
reduction of mass transfer limitations, the flow-associated 
shear stress has been reported to facilitate the maintenance 
of stem cell status and prevent spontaneous differentiation.[40] 
It may thus be speculated that cancer cells with stem cell-like 
features, including self-renewal ability, are preferentially 
Adv. Biosys. 2019, 3, 1800300
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maintained within perfused cultures due to the perfusion-
driven mechanical signal, mimicking interstitial fluid flow.
The role of the scaffold composition also deserves to be fur-
ther addressed in future studies. In this work, we decided to use 
a collagen-based scaffold, since collagen is a natural polymer 
and a major component of CRC matrix.[31] In our system, the 
role of the scaffold was mainly to provide a mechanical support 
to the tissue chunks, once placed within the perfusion chamber, 
and, by avoiding flowing of the medium around the chunks, 
to favor a perfusion as homogenous as possible through the 
whole chamber. The use of a collagen scaffold did not appear 
to mediate per se any major effect on tissue maintenance, as 
in pilot experiments static cultures performed with sandwich-
scaffolds resulted in a more severe tissue loss than static cul-
ture without scaffold (data not shown). However, it would be 
interesting to test the potential effect of an inert material (e.g., 
alginate), or of specific ECM components derived from human 
healthy colonic mucosa or CRC tissues, on survival and prolif-
eration of tumor and stromal cells within cultured tissues.
A proper comparative quantification of the ECM compo-
sition in cultured tissues was not possible due to the limited 
amount of material. A comparative proteomic analysis between 
fresh and cultured tissues, either under static or perfused con-
ditions, will be attempt.
In conclusion, thanks to its capacity to maintain TME hetero-
geneity, our system may allow drug testing within a more physi-
ological context. Although not suitable, in its current format, for 
 high-throughput drug testing, our system may be utilized for 
evaluation of patient-specific sensitivity to available therapeutic 
options. We envisage validating its ability to predict patient- 
specific clinical responses in the context of follow-up studies. 
Furthermore, our culture system may also prove suitable for stud-
ying basic aspects of cancer immune-biology or testing therapies 
whose efficacy is influenced by whole TME (e.g., drug-loaded nan-
oparticles,[41] targeting mesenchymal or immune cells, including 
TGF-β blockers,[42] bispecific antibodies,[43] or checkpoint inhibi-
tors,[44] currently under clinical investigation for CRC).
4. Experimental Section
Tumor Sample Processing: Human primary colorectal cancer 
specimens were obtained from consenting patients undergoing surgical 
treatment at the University Hospital Basel, St. Claraspital in Basel, and 
Ospedale Civico of Lugano, all in Switzerland. Use of human samples 
was approved by local ethical authorities (Ethikkommission Nordwest 
und Zentralschweiz, Study Protocol No. 2014-388). Clinico-pathological 
characteristics of tumor samples used are listed in Table S1 (Supporting 
Information). Tumor specimens were sampled by experienced 
gastrointestinal pathologists (L.M.T. and A.Z.) from freshly resected 
cancer tissues based on macroscopical evaluation, and maintained in 
Custodiol HTK solution (Dr. Franz Köhler Chemie GmbH) at 4 °C 
until used. To reduce the risk of contamination due to stool residues, 
specimens were rinsed in phosphate buffered saline (PBS) before 
processing, and incubated in a 10% Octenisept (Schülke & Mayr AG) 
solution for 5 min. After additional washings in PBS, tumor specimens 
were fragmented in 2 × 2 × 2 mm chunks using a scalpel. This size was 
selected based on preliminary experiments, and showed to allow the 
perfusion flow through the 8 mm diameter perfusion chamber, and 
displayed more limited cutting-related damages. Three randomized 
chunks from each sample were immediately embedded in optimal 
cutting temperature compound (OCT, Leica Biosystem) and preserved 
at −80 °C, as “Fresh” controls. Remaining fragments were weighted and 
used for cultures.
Tumor Specimen Culture under Static Conditions: Three randomized 
CRC fragments were placed into six-well polystyrene culture plates 
(Sigma) in DMEM/F12 (Gibco) supplemented with 5% pooled human 
AB serum (Blood Bank, University Hospital Basel), 2 × 10−3 m Glutamine 
(GlutaMAX-I, Gibco), 100 × 10−6 m HEPES (Gibco), 1 µg mL−1 Kanamycin 
sulphate (Gibco), 2.5 µg mL−1 Amphotericin B (Sigma-Aldrich A9528), 
20 µg mL−1 Metronidazol (Braun), 60 µg mL−1 Cefuroxim (Braun), 
10 µg mL−1 Ciproxine (Bayer Schering Pharma), 10 × 10−6 m N-acetyl-cysteine 
(Sigma-Aldrich), 20 × 10−6 m nicotinamide (Sigma-Aldrich), 25 ng mL−1  
epidermal growth factor (Stem Cell Technologies), 0.1 µg mL−1 
prostaglandin E2 (Tocris Bioscience). 3 d after, fragments were collected, 
weighted upon removal of superficial medium by absorbent tissues, and 
embedded in OCT for subsequent histomorphological evaluation.
Tumor Specimen Culture in Bioreactor under Perfusion: Two scaffold 
discs (8 mm diameter × 3 mm), made from a porous water-insoluble 
partial hydrochloric acid salt of purified bovine corium collagen sponge, 
known as Ultrafoam Collagen Hemostat (Avitene, Bard), were soaked in 
culture medium for 1 h at 37 °C.
Three randomized CRC fragments were placed between the discs in 
a sandwich-like configuration. The sandwich was assembled within a 
ring-shaped plastic holder closed on top and bottom by two EFTE nylon 
meshes (Fluorotex Sefar, 09-590/47) (Figure 1). The scaffold assembly 
was then placed into the perfusion chamber of a previously described 
perfusion-based bioreactor[30] (currently distributed as U-CUP by Cellec 
Biotek AG) and perfused with the same culture medium used for static 
cultures. Perfusion flow rate was set at 0.3 mL min−1, corresponding to a 
superficial velocity of 100 µm s−1,[39] as previously used for the generation 
of normal and tumor tissue-like constructs.[27,30,39,45,46] To assess the 
functionality of tumor-infiltrating lymphocytes, phytohemagglutinin 
(PHA, 1 µg mL−1, Remel Inc.) was added to the culture medium at 
the beginning of the culture. To evaluate viability and functions of 
mesenchymal stromal cells, human recombinant IL-17 (10 ng mL−1, R&D 
Systems) was added to the culture medium in the last 24 h of culture. 
To evaluate responsiveness to drug treatment, 5-FU (10 µg mL−1) 
was added to culture medium. In all experiments, a minimum of two 
bioreactors including a total of six tumor fragments per condition were 
used.
After 3 d, culture media were collected and assessed for cytokine 
content by ELISA. Fragments were collected, weighted upon removal 
of superficial medium by absorbent tissues, and embedded in OCT for 
histomorphological evaluation.
ELISA: IL-2, IFN-γ, and IL-6 release in culture media was assessed 
by using commercial IL-2 and IFN-γ ELISA kits (BD Biosciences), and 
human IL-6 Instant ELISA (BioLegend), respectively, according to 
standard protocols.
Histomorphological Assessment and Immunofluorescence (IF): 8 µm 
cryosections were obtained from cryopreserved, OCT embedded, freshly 
resected tumor chunks, or from fragments maintained in static or 
perfusion-based cultures. Cryosections were cut from a minimum of two 
up to ten different levels of the entire tissue block for each specimen, 
using a 25 µm trimming. Slides were fixed with formalin 4% and stained 
with hematoxylin and eosin (H&E) or used for IF analysis.
Upon H&E staining, abundance of epithelial and stromal components 
of neoplastic tissues was semiquantitatively assessed by an experienced 
gastrointestinal pathologist (L.M.T.), based on the evaluation of a minimum 
of two sections for each specimen and five regions of interest (ROI) per 
section at 40× magnification using Zeiss Axioskop 2 Plus microscope.
In IF studies, epithelial and stromal cells were identified upon 
staining with anti-EpCAM mouse mAbs (clone VU1D9, Cell Signaling), 
followed by Alexa Fluor 546-labeled goat antimouse polyclonal 
antibodies (A-11030, Invitrogen, 1:100), and anti-vimentin rabbit mAb 
(clone D21H3, Cell Signaling), followed by Alexa Fluor 488-labeled 
goat antirabbit polyclonal antibodies (A-11034, Invitrogen). Tumor-
infiltrating immune cells were identified by staining with anti-CD45-
specific Alexa Fluor 488 or Alexa Fluor 647 labeled mouse mAb (clone 
HI30, BioLegend), anti-CD3 Alexa Fluor 488 (clone UCHT1, BioLegend), 
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anti-CD19 Alexa Fluor 594 (clone HIB19, BioLegend), and anti-CD64 
Alexa Fluor 647 (clone 10.1, BioLegend). Endothelial cells were identified 
by staining with anti-CD31-specific DyLight 550 labeled mouse mAb 
(clone 31.3, Novusbio), and major ECM component collagen type 1 
was stained using a rabbit anti-human Collagen 1 (clone EPR7785, abcam). 
To evaluate proliferating and apoptotic cells, tissue sections were stained 
with anti-Ki67 488-labeled mAb (clone EPR3610, abcam), or anticleaved 
Caspase 3 (cC3) rabbit polyclonal antibodies (#9661, Cell Signaling), 
followed by Alexa Fluor 488-labeled goat antirabbit polyclonal antibodies 
(#A-11034, Invitrogen). Nuclei were counterstained by DAPI (Invitrogen).
Images were taken by using IX83 inverted microscope system 
(Olympus). Numbers of total nuclei or cells positive for vimentin, cC3, 
or Ki67 were analyzed using an automated image quantification program 
(CellProfiler 2.1.1, Broad Institute Imaging Platform).[47] For immune 
cells and CD31, numbers of total nuclei and positive cells were manually 
counted. For each specimen, five ROI per section were analyzed.
Statistical Analysis: Statistical significance of observed differences was 
tested using Wilcoxon matched-pairs signed rank test. Two-sided p-values 
were considered significant at p-values < 0.05 (*p ≤ 0.05; **p ≤ 0.01). 
Statistical analysis was performed using GraphPad Prism version 7.0c 
(GraphPad Software, La Jolla, CA, www.graphpad.com).
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Supporting Information is available from the Wiley Online Library or 
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ABSTRACT: Immunotherapy has emerged during the past two decades as an
innovative and successful form of cancer treatment. However, frequently, mechanisms
of actions are still unclear, predictive markers are insuﬃciently characterized, and
preclinical assays for innovative treatments are poorly reliable. In this context, the
analysis of tumor/immune system interaction plays key roles, but may be unreliably
mirrored by in vivo experimental models and standard bidimensional culture systems.
Tridimensional cultures of tumor cells have been developed to bridge the gap between in
vitro and in vivo systems. Interestingly, deﬁned aspects of the interaction of cells from
adaptive and innate immune systems and tumor cells may also be mirrored by 3D
cultures. Here we review in vitro models of cancer/immune cell interaction and we
propose that updated technologies might help develop innovative treatments, identify
biologicals of potential clinical relevance, and select patients eligible for immunotherapy treatments.
KEYWORDS: tumor inﬁltrating cells, tumor microenvironment, three-dimensional cultures, tumor engineering,
tumor-immune cell interaction
■ INTRODUCTION
The interaction between cancer cells and the immune system
plays decisive roles in tumor outgrowth and in the control of
tumor progression.1 Indeed, tumor promoting inﬂammation2
and the ability to escape immune-mediated destruction3 do
represent bona ﬁde cancer hallmarks.4 Studies on clinical
specimens have provided a powerful validation of results
emerging from experimental models and highly signiﬁcant
prognostic correlations have emerged from the analysis of
human tumor inﬁltration by cells of the innate and adaptive
immune system.5 Most importantly, immunotherapies now
represent routine treatments of patients with cancers of diﬀerent
histological origin.6
A variety of monoclonal antibodies (mAbs) have been
routinely used for almost two decades in cancer treatment.7 In
many instances, they were developed to prevent the binding of
receptors expressed by tumor cells by growth factors promoting
their proliferation. However, mechanisms mediated by immune
cells including phagocytosis and antibody-dependent cell
cytotoxicity (ADCC) have frequently been shown to underlie
their clinical eﬀectiveness.8 Indeed, critically depending on their
aﬃnity and isotype,9 therapeutic mAbs may mediate target cell
cytotoxicity elicited by lymphocytes or myeloid cells expressing
activating Fc receptors. A main issue in mAb-mediated
immunotherapy, particularly regarding innovative reagents
recognizing markers expressed by immune cells, is whether it is
desirable to kill target cells or rather to merely inhibit their
interaction with speciﬁc ligands without killing them. In the latter
case, the use of mAbs binding inhibitory Fc receptors would be
recommended. Considering current uncertainties concerning
the mechanism of action of several therapeutic mAbs,10 isotype is
emerging as critical for success or failure of reagents recognizing
the same target molecule. On the basis of this background,
reagents characterized by diﬀerential aﬃnity and ability to bind
Fc receptors expressed by eﬀector cells are continuously being
developed.11,12 Moreover, bispeciﬁc mAbs speciﬁcally targeting
deﬁned eﬀector functions to tumor cells are presently in
advanced clinical experimentation.13
Most importantly, in the past decade, therapeutic mAbs
recognizing immunological checkpoints have been successfully
tested and utilized in clinical practice.14 The rationale underlying
their development is that they are supposed to prevent the
interaction between activation markers expressed by antigen
speciﬁc T cells and their ligands expressed by antigen presenting
and/or tumor cells, physiologically resulting in the inhibition of
adaptive T cell responses. Releasing the brakes of antitumor
responses has proven eﬀective in a variety of cancers.15 However,
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mechanisms of action have not been fully clariﬁed and markers
predictive of clinical responsiveness still need to be satisfactorily
identiﬁed.10 On a similar line anti-CD47mAbs have been used to
promote tumor cell phagocytosis by macrophages.16,17
Adoptive cancer immunotherapies have also been developed
in the past two decades.18 They are based on the administration
to patients of autologous cells following in vitro culture and
expansion. Current adoptive treatments usually capitalize on the
use of T cells from patients transduced with genes encoding
conventional or enhanced-avidity HLA-restricted T-cell recep-
tors recognizing tumor-associated antigens, or chimeric HLA-
unrestricted antigen receptors (CAR) recognizing surface
molecules highly expressed by malignant cells. While these
technologies are mostly used in the treatment of hematological
malignancies ongoing clinical trials also target solid malignancies.
Following these breakthroughs, a large number of innovative
biologicals and procedures addressing cancer immunotherapy
are being generated and tested in clinical trials and this research
ﬁeld is facing an unprecedented explosion of knowledge and
applications, urging the development of adequate assays for
preclinical assessments and for the selection of patients
potentially beneﬁting from treatment.
■ MODELING HUMAN TUMOR-IMMUNE SYSTEM
INTERACTIONS: THE PRESENT
Substantial knowledge underlying the development of ther-
apeutic mAbs and innovative immunotherapy procedures has
been gained from in vivo experimental animal models.1,3,19 In
vitro studies utilizing human cells have provenmore problematic,
not least due to diﬃculties inherent in the availability of suﬃcient
numbers of freshly derived tumor or immune cells and of
autologous immune/tumor cells systems. Furthermore, the
generation of established tumor cell lines from clinical specimens
remains a major challenge and the intrinsic heterogeneity of
human cancers, in spite of a similar histological origin, must not
be underestimated.
Nevertheless, conventional in vitro models have proven of
paramount importance in human immunology and, in particular,
in tumor immunology. 51Cr release assays20 have represented the
ultimate tests for the identiﬁcation of human tumor associated
antigens,21,22 and standard bidimensional cultures have allowed
the expansion of tumor inﬁltrating lymphocytes,23 the generation
of tumor speciﬁc T cell clones,22 and the monitoring of the
eﬀectiveness of therapeutic antitumor vaccinations.24 Presently,
ﬂow-cytometry techniques based on the detection of cells
expressing T-cell receptors recognizing antigenic peptides
restricted by deﬁned HLA determinants, for example, multimers,
frequently complemented by the analysis of intracellular cytokine
expression upon antigenic triggering represent routinely used
technologies for the evaluation of adaptive T cell responses.
These techniques are frequently accompanied by so-called
Elispot assays identifying individual cells producing speciﬁc
cytokines upon antigenic stimulation. Combinations of these
techniques are currently included in the monitoring of antigen
speciﬁc T cells responses in patients undergoing immunotherapy
treatments (Figure 1).25
Cytotoxic activities of NK lymphocytes against malignant cells
opsonized by antibody treatments are typically assessed in vitro
by using tumor cell line monolayers as targets. Similar assays are
also used to analyze the cytotoxic or cytostatic potential of other
eﬀector cell types expressing Fc receptors, including macro-
phages, dendritic cells (DCs), and neutrophils. Tumor cell
proliferation or 51Cr release are classically used as read-out.
Phagocytosis of tumor cells by macrophages is usually tested by
admixing diﬀerentially labeled eﬀector and tumor cells in the
presence or absence of biologicals of potential therapeutic
relevance and using ﬂow-cytometry to identify phagocytosed
cells.26
Figure 1. Currently used in vitro assays for the analysis of tumor/T lymphocyte interactions. Antitumor functions of human immune cells are currently
assessed in vitro by a variety of established tests. They include the analysis of the expression of T-cell receptors recognizing tumor-speciﬁc or tumor-
associated antigens (tetramer or multimer staining, left panel). Expression of cytokine genes or production of speciﬁc factors upon culture in the
presence of tumor cells in standard bidimensional conditions are usually assessed by quantitative PCR (middle panel A) or by ﬂow-cytometry upon
intracellular staining (middle panel B). Elispot assays evaluate the numbers of cytokine producing cells, as detectable following culture in the presence of
tumor cells or antigen presenting cells pulsed with speciﬁc peptides in standard bidimensional conditions (right panel).
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■ WHY ARE INNOVATIVE MODELS OF TUMOR
IMMUNE SYSTEM INTERACTION IMPORTANT?
In vitro data consistently indicate that, in deﬁned assay
conditions, at least T and NK lymphocytes and macrophages
are able to eﬃciently elicit antitumor functions. Notably,
however, cytotoxic tumor inﬁltrating T lymphocytes are
frequently disfunctional in vivo,27 as also indirectly suggested
by the clinical eﬀectiveness of immunological checkpoints
targeted treatment.28 Furthermore, immune-histochemical stud-
ies suggest that solid tumors most frequently lack detectable NK
cell inﬁltration.29,30 More importantly, with a few exceptions,
including colorectal cancer (CRC), macrophage inﬁltration of
solid tumors is usually associated with poor prognosis.31
Discrepancies between in vivo and in vitro functional proﬁles
of immune cells have stimulated research aimed at unraveling
mechanisms and conditions favoring T cell anergy and
exhaustion, pro-tumor macrophage polarization, defective NK
cell recruitment and, ultimately, tumor escape from immune
surveillance. A variety of diﬀerent cell types including
alternatively activated macrophages,32 regulatory T cells
(Treg),33 and myeloid derived suppressor cells34 have been
considered. Furthermore, immunosuppressive mechanisms at
work in the tumor microenvironment have been shown include
hypoxia and adenosine receptor triggering,35,36 and expression of
ligands for immunological checkpoints (see above).
Earlier reports in the past had suggested that oxygen levels may
dramatically aﬀect lymphocyte responsiveness.37 More recently,
a large number of important studies appear to indicate that
hypoxia and speciﬁc metabolic conditions occurring with tumor
tissues might provide a unifying background for a variety of
previously observed immunosuppressive mechanisms and
decisively hamper the potential eﬀectiveness of anticancer
immune responses. Indeed, hypoxia has been shown to promote
immune tolerance by Treg recruitment.38 Intriguingly, ex-
pression of PD-1 immunological checkpoint has been related
to metabolic alterations occurring within tumor tissues.39,40 A
key point appears to be represented by the competition for
glucose between tumor cells and T-cell receptor triggered,
antigen speciﬁc T cells, both characterized by aerobic
glycolysis.41−44 Moreover pro-tumor M2 macrophage activation
has also been associated with increased glycolysis,45,46 and the
development of myeloid derived suppressor cells within the
tumor microenvironment has been related to hypoxia (Figure
2).47
While these phenomena have been extensively characterized in
vivo and ex vivo, although mostly in experimental models, they
also suggest the fascinating possibility of generating innovative in
vitro models adding new dimensions to the analysis of the tumor
microenvironment in highly controlled conditions and allowing
the preclinical screening of biologicals and small molecules in
conditions closer to in vivo features of the human tumor
microenvironment.
Figure 2. Metabolic alterations of the tumor microenvironment aﬀecting tumor/immune cell interactions. The in vivo tumor microenvironment is
characterized by speciﬁc metabolic features, including, among others, hypoxia and aerobic glycolysis, resulting in competition for glucose and other
nutrients between tumor and immune cells and production of lactic acid. As a result, a variety of eﬀector functions of diﬀerent immune cell
subpopulations are inhibited. Furthermore, functions of antigen presenting cells are also aﬀected. At diﬀerence with standard assays, tridimensional
culture systems may at least partially mirror these conditions in vitro.
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■ MODELING HUMAN TUMOR−IMMUNE SYSTEM
INTERACTIONS: THE THREE-DIMENSIONAL
APPROACH
To address the high attrition rate in the development of
innovative anticancer compounds a variety of tridimensional
culture models have been developed in the past.48 They have
revealed the major role played by the architecture of cell growth
in the deﬁnition of the gene expression proﬁles of tumor cells,
their metabolic activities, and their sensitivity or resistance to
drug treatment.49−51 On the basis of these ﬁndings, innovative
high throughput drug screening platforms have been generated
and are currently utilized in pharmacological research. In initial
studies, multicellular spheroids were obtained by preventing the
adhesion of tumor cells on plastic cell culture surfaces.52 Later,
scaﬀolds, hanging drops, and microﬂuidics-based technologies
were successfully developed.53
Control of spheroid size has allowed the generation of
structures characterized by controlled levels of hypoxia and
perfused bioreactors have proven to be useful to generate tissue-
like structures from established human tumor cell lines.54,55 In
this context, it is also remarkable that human cancer cells
endowed with tumor initiating capacity, so-called tumor
initiating cells (TIC) or cancer stem cells (CSC), from tumors
of diﬀerent histological origin, including colon, breast, and CNS,
are typically characterized by the ability of generating spheres
that are able to slowly replicate with asymmetric divisions.56,57
Models of higher complexity are continuously being
developed58,59 aiming at including additional components of
the tumor microenvironment of proven relevance in clinical
course and in the development of resistance to treatment.
Furthermore, physical conditions within tumor tissues and the
possibility of reliably reproducing them in vitro are increasingly
attracting the attention of the scientiﬁc community. In particular,
microﬂuidics models have been generated60 to address sensitivity
to drugs and dissemination of cancer cells,61 tumor lymphatic
vessel interaction,62 and homing of tumor cells to deﬁned
metastatic niches.63 Intriguingly, however, the ﬁrst 3D culture
models had initially been developed to address immune
responsiveness to solid tumor allografts.52
In view of this background it is surprising that only relatively
few studies have addressed the eﬀects of 3D culture of tumor cells
and on their sensitivity to lymphocyte eﬀector activities.
Pioneering works suggested that tumor cells cultured in 3D
were poorly targeted by cytokine activated lymphocytes64 and
that the disruption of these architecture represented an
important prerequisite for a full elicitation of antitumor
cytotoxicity.65 More recently, we and others observed that T
cell eﬀector functions are severely impaired when target cells are
structured in 3D architectures.66,67
Diﬀerent mechanisms have been proposed. Dangles-Marie et
al. suggested that decreased expression of heat shock protein-70
by tumor target cells might result in ineﬃcient antigen
presentation.68 We observed that cells from established
melanoma cell lines may down-regulate expression of HLA and
melanoma diﬀerentiation antigens following culture in sphe-
roids.69 Interestingly, decreased expression of Melan-A/MART-
1 diﬀerentiation antigen has also been observed in hypoxic areas
of clinical melanoma specimens.70
On the other hand, lactic acid is produced to increasing extents
in cells cultured in 3D, as compared to their 2D counterparts.69,71
Notably, concentrations of lactic acid produced in these
conditions are suﬃcient to signiﬁcantly inhibit the elicitation of
eﬀector functions of antigen speciﬁc cytotoxic T lymphocyte
(CTL) clones, thus providing an important link between typical
metabolic features of tumor cells and T cell functional
impairment.
Figure 3. Tumor cell spheroids as targets of immune cell eﬀector functions. Tumor cell spheroids generated by diﬀerent procedures have been used to
verify the eﬀects of culture in tridimensional conditions on a variety of immune cell functions. T-cell clones recognizing melanoma-associated antigens
have been cocultured with melanoma cells (panel A). CAR-transduced cells for adoptive treatments have similarly been tested. Functions of monocyte/
macrophage lineage cells, including phagocytosis and antigen presentation have also been assessed. Moreover, antibody-dependent cell cytotoxicity
mediated by NK cells has been explored using target cells cultured as spheroids (panel B).
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NK lymphocyte inﬁltration has also been studied in scaﬀold-
free and 3D Matrigel-based models72,73 and the impaired
cytotoxic ability of natural killer (NK) cells against targets
cultured in tridimensional architectures has also been reported.74
In particular, the resistance of tumor cells to NK lymphocyte-
mediated cytotoxicity in 3D gliomamodels has been attributed to
increased HLA-E expression by tumor cells.75 NK and Treg
interaction with breast cancer cells in 3D has been shown to
result in increased production of CCL4-attracting inﬂammatory
cells of pro-tumor signiﬁcance.73 Instead, despite their potential
relevance in the cancer microenvironment, there is a lack of
studies investigating B-cell tumor cell interaction in 3D
architectures. Most recently, models based on microﬂuidic
technology have also been proposed to analyze tumor/
lymphocyte interaction.76
Interestingly, recently, an advanced model based on hanging
drop technology and including ﬁbroblasts, additional key
components of the tumor microenvironment has been
successfully used to explore the ability of diﬀerent types of
immune cells to display their eﬀector, antitumor potential,77 as
mediated by therapeutic mAbs.
A number of studies on tridimensional modeling have focused
on lymphocytes. However, macrophages and other myeloid cells
are also frequently inﬁltrating human cancers.78 Murine and
human cells of the monocyte/macrophage lineage may be
polarized by cytokine treatment into M1 macrophages endowed
with antitumor potential or M2 macrophages which have been
shown to be rather tumor-supportive and characterized by a pro-
angiogenic functional proﬁle.32 It is worth noting that the M1/
M2 polarization notion represents a useful oversimpliﬁcation of a
process more realistically described as a continuum.79 Never-
theless, the culture of monocytes and macrophages within
tridimensional tumor spheroids has been shown to profoundly
aﬀect their diﬀerentiation and functional proﬁles.80−82 A
coculture of human and murine macrophages together with
squamous cell carcinoma cells in 3D architectures, in the
presence or absence of ﬁbroblasts, has been shown to promote
their polarization toward an M2 functional proﬁle and induce
metalloproteases (MMP) production, thereby favoring tumor
invasiveness, as related to increased extracellular matrix
degradation.83 Similar observations were also made in experi-
ments performed by using breast,84,85 thyroid,86 hepatocellular,87
and bladder88 cancer cell lines. In all these cases alterations of the
chemokine secretome in 3D cultures including tumor cells and
macrophages in the presence or absence of ﬁbroblasts were
consistently observed. NSCLC cells cultured in aggregates have
been shown to preferentially attract M2 macrophages, which, in
turn promote their epithelial-mesenchymal transition (EMT)
andmigration, as observed by usingmicroﬂuidic devices.61 In this
study macrophages cultured in diﬀerent conditions, potentially
related to intermediate polarization stages were comparatively
analyzed. Most recently, tumor cell migration in a 3D
extracellular matrix was also reported to be enhanced by
macrophage-secreted TNFα and TGFβ1.89
On the other hand, importantly, antigen presentation and
diﬀerentiation capacity of DCs have been shown to be inhibited
by lactic acid produced by tumor cells in 3D cultures including
microﬂuidic models (Figure 3).71,90 These data indicate that
tridimensional models could also be advantageously used to
analyze, in controlled conditions, the interactions occurring in
vivo between tumor cells and cells of the monocyte/macro-
phage/dendritic cell lineages (Table 1).
Interestingly, neutrophil polarization similar to functional
features similar to those detected in macrophages, has also been
recently reported.82,91 However, possibly due to diﬃculties
inherent in a granulocyte culture, the eﬀects of incubation with
tumor cells cultured in 3D on their polarization have not been
addressed so far, and further research in this area is warranted.
■ MODELING HUMAN TUMOR−IMMUNE SYSTEM
INTERACTIONS: THE BIOMATERIALS
In addition to cell composition and structural architecture, the
extracellular matrix (ECM) also plays key roles in the tumor
microenvironment, critically aﬀecting cancer cell dynamics and
response to treatment in vivo and in vitro.92,93 To address these
issues, a variety of biomaterials are currently being evaluated to
help mimic tumor microenvironment features. While a thorough
analysis of biomaterials used in 3D cultures of tumor cells94
clearly exceeds the purposes of this review, it might be of interest
to recapitulate recent advances in this area, as related to the
modeling of tumor-immune system interaction.
The use of a decellularized matrix95 from cancer specimens has
been proposed.96 However, harsh decellularization treatments
might result in loss of ECM components and alterations of its
ultrastructure.95 Furthermore, ECM from human tissues are not
commercially available. Notably, ECM composition may be
remarkably diﬀerent in cancers of similar histological origin, thus
complicating standardization. For instance, in CRC, while
collagen type 1 is the single most represented ECM component,
laminin and ﬁbronectin may also be present to highly diﬀerent
extents in diﬀerent samples.97 Useful simpliﬁcations of these
complex issues might reside in the use of single most represented
components98 or commercially available ECM mixtures from
experimental animals, such as Matrigel or Cultrex.86,99 Even in
these cases, however, diﬀerences from batch to batch of
commercial products should not be underestimated. Agar,
agarose, and hyaluronic acid have also been used for spheroid
formation.100
In a number of reports the tumor−immune system interaction
in 3D structures has been investigated in the absence of
scaﬀolds.66−69,72,88 In these studies spheroids might be right-
eously considered as building blocks of in vitro developed tumor
tissues, also considering the ability of cancer cells to produce
ECM components. Alternatively, collagen has been used as
scaﬀold or to coat microﬂuidics devices.61,83,89,101 Matrigel and
Cultrex have been widely utilized85,86,102 and the use of alginate84
and synthetic materials has also been investigated.103,104
Table 1
3D culture system ref
cytotoxic T
lymphocyte
activity assays
spheroids 52, 64, 66, 67
engineered tumor models 76, 110
NK cytotoxicity
assays
spheroids 74
monocytes/
macrophage/DC
spheroids 71, 80, 81, 116
−tumor cell
interaction
microﬂuidic devices 60, 90
therapeutic mAbs
(ADCC, Bispeciﬁc
Abs)
spheroids 12−14, 65, and
77
drug tests in
engineered TMEa
in vitro engineered tissue models
(spheroids, microﬂuidics devices
bioreactors)
51, 54, 55, 58,
59, 117, and
118
aTME: tumor microenvironment.
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On the other hand, progress in the characterization of natural
biomaterials and in the engineering of synthetic ones, combined
with advances in the understanding of biological processes, have
widely extended the range of compounds under investigation.94
Multifunctional biomaterials targeting deﬁned cell populations
and favoring cell-to-cell interactions and crosstalk have been
designed. Some of them are able to promote durable immune
responses by protecting agents from degradation and providing
sustained signals to host immune cells.105−108 Therefore,
biomaterials are evolving from mere structural supports into
tools interacting with cells and tissues to induce and modulate
biological responses.
It is tempting to speculate that 3D models of cancer-immune
cell interaction will prove extremely useful for the preclinical
testing of innovative biomaterials.
■ MODELING HUMAN TUMOR−IMMUNE SYSTEM
INTERACTIONS: AN OUTLOOK
Tumor tissues include a large variety of nonmalignant cells. Their
numbers may vary widely depending on the histological origin of
the cancer. For instance, in melanoma, cancer cells usually
account for >90% of the cells detectable within clinical
specimens. In contrast, malignant cells represent a mere 10%
of cells from cancer tissues in Hodgkin lymphoma. The mutual
interaction between malignant and nontransformed cells is
highly dynamic and critically aﬀects both components of the
tumor microenvironment.109 In the recent past, engineered
tumor tissue constructs have successfully been used to investigate
the chemo-attractive potential of tumor and tumor inﬁltrating
cells.110
Most importantly, the composition of the tumor micro-
environment is of decisive relevance to predict the clinical course
of the disease111,112 and the response to treatment.113 This
background urges the development of techniques allowing the
investigation of functional features of the human tumor
microenvironment in controlled conditions. However, a number
of hurdles need to be preliminarily addressed. For many human
cancers, no reliable experimental model is available. Moreover,
the characteristics of the immune systems of a variety of inbred
murine strains poorly mirror those detectable in patients’
populations.114 On the other hand, generation of established
cell lines from clinical specimens is only feasible in a limited
number of human cancer types.
To obviate these diﬃculties the generation of patient-derived
xenografts (PDTX) in immune-deﬁcient mice has been
proposed for personalized assessment of the sensitivity of
tumor cells to deﬁned chemotherapy regimens.115 These assays
are widely used in basic and translational research. However, they
are characterized by a number of limitations. In vivo growth of
xenografts might be diﬃcult or require relatively long time spans,
particularly for tumors of speciﬁc histological origin, such as
prostate cancers. In addition, human tumor cell growth might be
limited by the lack of cross-species activity of a variety of factors
produced in the xenograft microenvironment. Most importantly,
PDTX technologies are poorly suitable for the evaluation of
biologicals and small molecules targeting tumor-immune system
interaction, since human interstitial cells are rapidly replaced by
murine cells in successfully growing xenografts, and human
inﬁltrating immune cells are lost.
Ideally, innovative assays should include as many cellular
components of the microenvironment of a speciﬁc cancer as
possible. This represents a major challenge since primary and
metastatic tumor niches may be substantially diﬀerent.
Furthermore, even in cancers of similar histological origin, the
tumor microenvironment is highly variable and its composition
might also be related to factors, for example, commensal ﬂora in
colorectal cancers poorly amenable to in vitro modeling.
To attempt to address these issues, at least in part, Majumder
et al. used entire fragments of clinical specimens to predict the
eﬀectiveness of chemotherapy.97 Limitations associated with
these approaches are mainly inherent in the short timing
available for testing, since a major loss of tumor viability,
particularly for carcinoma tissues rapidly occurs following
surgical excision. It is tempting to speculate that tumor fragments
might serve as precious tools to assess the eﬀectiveness of
anticancer treatments prior to their administration to patients. A
similar approach would likely require the establishment of
innovative culture approaches preserving viability and functional
potential of the diﬀerent cell types included in the tumor
microenvironment for time periods allowing the elicitation of
anticancer immune eﬀects.
Figure 4. Innovative tridimensional models of tumor/immune cell interaction. Innovative models of tumor immune system interaction may take
advantage of the use of established cell lines producing tissue-like structures upon culture in perfused bioreactors. Furthermore, the use of ex vivo
cultured fragments from surgically excised cancers could also be envisaged. In either case, combinations of immune cells, biologicals and/or small
molecules could be tested for their eﬀects on malignant cells.
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Indeed, advanced immunotherapy protocols utilizing bio-
logicals targeting immunological checkpoints presently provide
signiﬁcant beneﬁt to sizable fractions of treated patients, varying
in cancers of diﬀerent histological origin. However, these
treatments are also characterized by a high incidence of severe
adverse events. Although the identiﬁcation of markers predicting
responsiveness currently represents an active research area10
relatively large numbers of patients undergo highly toxic
treatments without clinical beneﬁt. Personalized in vitro models
could help to identify responsive patients prior to the initiation of
therapy and novel combination approaches.
On the other hand, fragments from clinical specimens cannot
be used for high throughput screening and may only be utilized
to validate data emerging from less heterogeneous and more
standardized models. Therefore, the establishment of more
complex and realistic models of the tumor immune system
interaction in vitro still represents a challenge (Figure 4).
■ CONCLUSIONS
It is all too obvious that in vitro models will never reproduce the
enormous complexity of cancer growth in vivo. Nevertheless,
they might provide the opportunity to test, in highly controlled
conditions, basic science hypotheses and innovative treatments.
The major advances of the past two decades have boosted an
enormous interest in tumor immunobiology and immunother-
apy, leading to unprecedented numbers of preclinical and clinical
studies. Assessment of the eﬀectiveness of innovative treatments
will require the establishment of innovative in vitro technologies.
Remarkably, the potential toxicity of these treatments will also
have to be tested. Cytokine release and tumor lysis syndromes,
and on target/oﬀ tumor reactivity do represent major concerns in
this area and also urge the establishment of adequate in vitro
models.
On the other hand, the analysis of tumor genomes and of the
tumor microenvironment is challenging current tumor classi-
ﬁcation and staging criteria, usually underlying the selection of
patients for standard therapeutic protocols. The emerging quest
for personalized treatments might provide an additional
incentive for the development of innovative culture technologies.
On the basis of this background it is easy to predict a bright
future for the in vitro modeling of tumor immune-system
interactions.
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